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ABSTRACT 
 
Investigation of the antidiabetic activity of Cnicusbenedictus L. in rats. 
R. BAMBOUKOU BEKALE 
M. Pharm. Pharmaceutical Sciences thesis: School of Pharmacy, University of the 
Western Cape 
Diabetes Mellitus, one of the major diseases affecting human population all over the 
world has caused significant morbidity and mortality. The management of this 
condition has raised the demand of safe and cost effective remedial measures due to 
several side effects associated with the present use of modern medicines. Thus, it is 
crucial to explore other options for diabetes management such as the use of medical 
plants. Cnicus benedictus L. is one of the known plant species used by traditional 
medicine practitioners in South Africa for the treatment of various ailments including 
inflammatory conditions, pain and diabetes. Even though the plant species has been 
extensively studied, scientifically, no evidence exists in literature to corroborate the 
claim made by traditional medicine practitioners of its therapeutic success in the 
treatment of diabetes and pain. 
Therefore, the objectives of this present study were: to investigate the antidiabetic 
activity of C. benedictus using leaf methanol extract of the plant species on animal 
model involving male and female Albino rats; to investigate the antinociceptive 
activity of the plant species on mice; to determine the safety profile of the plant by 
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investigating the acute toxicity and to carry out HPLC study in order to characterize 
the plant species.  
Animals were divided into groups of six each and fasted overnight prior to the 
induction of diabetes in rats using Streptozocin (STZ). The plasma glucose was 
measured at intervals of 30 min for 4 hours by means of a glucometer. Cnicus 
benedictus (100 – 400 mg/kg, i.p.) significantly reduced the blood glucose 
concentrations of fasted normal rats with percentage maximum reduction ranging 
from 46 to 79% and chlorpropramide (250 mg/kg, i.p.) significantly reduced the 
blood glucose concentrations of fasted normal rats by 84%. Cnicus benedictus (100 – 
400 mg/kg, i.p.) significantly reduced the blood glucose concentrations of STZ-
induced diabetic rats with percentage maximum reduction ranging from 44.82 to 
66.04% and chlorpropramide (250 mg/kg, i.p.) significantly reduced the blood 
glucose concentration of STZ-induced diabetic rats by 71.71%. 
In the oral glucose tolerance test, administration of leaf methanol extract of Cnicus 
benedictus (100 – 400 mg/kg, i.p.) following oral glucose load on fasted 
normoglycaemic rats significantly reduced the increased blood glucose 
concentrations with percentage maximum reduction ranging from 42.45 to 70.75%. 
Chlorpropramide (250 mg/kg, i.p.) following oral glucose load on fasted 
normoglycaemic rats significantly reduce the increased blood glucose concentration 
with a percentage maximum reduction of 79.04%.   
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In acetic acid writhing test, animals were divided into groups of eight per dose. 
Cnicus benedictus (25-400 mg/kg, i.p.) significantly reduced the number of writhes in 
mice with percentage inhibition of the writhes ranging from 67.95 to 73.71%. 
Indomethacin (20 mg/kg, i.p.) and paracetamol (500 mg/kg, i.p.) significantly 
reduced the number of writhes in mice with percentage inhibition of 75.44 and 
69.18% respectively. Combined treatment of lowest and sub-effective doses of 
C.benedictus (12.5 mg/kg, i.p.) and indomethacin (10 mg/kg, i.p.) significantly 
reduced the writhes with a percentage inhibition of 58.32%.  
In hot plat test, animals were divided into groups of eight per dose. Cnicus benedictus 
(25-400 mg/kg, i.p.) significantly delayed the reaction times of the mice to hot-plate 
thermal stimulation. Morphine (10 mg/kg, i.p.) significantly delayed the reaction time 
of the mice to the hot-plate stimulation.  
The no-adverse-effect-level (NOAEL) of leaf methanol extract of Cnicus benedictus 
was obtained at 3200 mg/kg (p.o.) and the LD50 value of the plant species was found 
to be 4000 mg/kg (p.o.). 
The HPLC fingerprint of the leaf methanol extract of Cnicusbenedictus showed 
distinct peaks at the following retention times of 6.387, 14.628, 18.431, 23.228 and 
29.829 min.  
In conclusion, the data obtained showed that leaf methanol extract of Cnicus 
benedictus possesses both antidiabetic and antinocipetive activities. 
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CHAPTER 1 
INTRODUCTION 
 
According to Kinghorn et al. (1993), natural products and their derivatives represent 
more than 50 % of all drugs in clinical use in the world and higher plants contribute 
no less than 25 % of the total. The world is currently undergoing a rapidly growing 
interest in natural and traditional herbal remedies as a source of new commercial 
products in health shops and pharmacies. Commonly known examples of plant-
derived medicines include atropine, codeine, colchicine, digoxin, morphine, quinine, 
reserpine and new cancer drugs such as taxol and vincristine (Kinghorn et al., 1993). 
 
The curative actions of medicinal plants or phytomedicines (“phyto” means plant) and 
derivatives are due to the presence of mixture of different chemical entities. Chemical 
entities are defined as pure chemical compounds used for medicinal purposes. The 
active chemical compounds in medicinal plants are called secondary metabolites. A 
secondary metabolite can have more than one pharmacological activity because they 
are multifunctional compounds. These metabolites act individually or in synergy in 
direct or indirect pathways to treat diseases or improve and maintain health. In order 
to work as therapeutic agents, secondary metabolites need to interfere with a 
molecular target in the human body. Secondary metabolites are commonly classified 
in groups such as amino-acids, alkaloids, flavonoids, essential oils, glycosides, 
lectins, glycoproteins tannins, quinones, coumarins, terpenoids and so on(Van Wyk et 
al., 1997 ; Das Prajapati et al., 2003 ; Light et al.,2005 ; Van Wyk et al.,2012). 
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Several people all over the world still rely on medicinal plants or plant-derived 
medicine for daily healthcare needs as natural substitute to synthetic chemicals. 
Approximately 80% of the populations in Africa still rely on traditional medicinal 
plants to cure many kinds of ailments especially in rural areas. These herbal remedies 
are an important part of African cultural heritage transmitted from one generation to 
the next based on trial and error over many centuries (Das Prajapati et al., 2003). 
 
South Africa is known to have a remarkable biodiversity of over 30 000 species of 
higher plants with approximately 3 000 of them used for medicinal purposes and 
some are commonly traded as medicinal plants. It is estimated that around three 
million South Africans in rural and urban areas are reliant on traditional medicinal 
plants only or in combination with modern medicine (Van Wyk et al., 1997). 
 
According to the world health organization (World Health Organization, 2008), 
traditional medicine is the combination of skills, knowledge and practices based on 
the theories, believes or experiences indigenous to different cultures and used for 
diagnosis or treatment of illness but also for prevention, improvement or maintenance 
of health. The adaptation of traditional medicine in different regions is done 
regardless of advanced international standards and methods of evaluation. Several 
countries do not have national policies to regulate practitioners, practices and 
traditional medicine remedies. For example, most traditional medicines prepared by 
traditional healers in South Africa are likely to develop microbial contamination at 
any stage of the preparation process due to the lack of proper hygienic settings during 
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preparation, handling and storage of herbal products (Ernest., 2002 ; Govender et al., 
2006 ; World Health Organization,2008). 
 
Since there is less stringent regulatory authority for medicinal plants products, South 
Africa is moving towards basic research on herbal medicinal remedies to ensure the 
quality, safety and authenticate the therapeutic claims made by traditional healers or 
herbalists(Govender et al., 2006 ; Van Wyk et al.,2012). 
 
The therapeutic claims made by traditional healers range from curative diseases to 
chronic diseases such as diabetes.  Diabetes Mellitus, one of the major diseases 
affecting human population all over the world, has caused significant morbidity and 
mortality. The condition can be defined as an endocrine disorder characterized by 
glycosuria and hyperglycaemia. Diabetes Mellitus is due to either the inability of the 
pancreas to produce enough insulin or the inability of the body to correctly use the 
insulin produced. According to the annual report of International Diabetes Federation 
(IDF), 382 million people were living with diabetes in 2013 from which 80% of 
people live in low and middle-income countries. IDF predicts this number to rise to 
592 million people by 2035 (IDF, 2013). 
 
Medical researchers are still working on the management of Diabetes Mellitus which 
is still a big challenge for them. The management of this condition has raised the 
demand of safe and cost effective remedial measures because of several side effects 
associated with the present use of modern medicines (Preethi, 2013).Thus, it is 
crucial to explore other options for diabetes management such as the use of medicinal 
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plants. Traditional plant based remedies are still the first choice in the developing 
countries because of their cost effectiveness, easy availability and minimum or no 
side effects  (Watt et al., 1962 ; Okigbo et al., 2006). 
 
In this present study, we are investigating the antidiabetic activity and safety profile 
of a medicinal plant called Cnicus benedictus.L. The plant species is known to have 
pharmacological properties such as antimicrobial, anti-inflammatory and 
antiproliferative effects. Those pharmacological effects have been proven with animal 
studies but no clinical outcomes have been published. The antimicrobial activity has 
been proven against Bacillus subtilis, Brucella species, Escherichia coli, Proteus 
species, Streptococcus faecalis, Staphylococcus aureus and Pseudomonas aeruginosa 
due to the presence of sesquiterpene lactone cnicin (Vanhaelen-Fastre, 1968; 
Vanhaelen-Fastre, 1974; Chevalier, 2000; Van Wyk et al., 2004). 
 
The pharmacokinetics studies show that cninin, the main component of Cnicus 
benedictus has a mild antiinflammatory activity due to inhibitory effects on cyclic 
AMP, phosphodiesterase and histamine release in mast cells (Mascolo et al., 1987; 
Schneider et al., 1987). Studies investigating the antineoplastic and cytotoxic effects 
demonstrate that the constituent, cninin and arctigenin, show anti-tumour activity via 
inhibition of cellular DNA, RNA or protein synthesis (Vanhaelen-Fastre, 1971 ; 
Cobb, 1973 ; Ryu et al., 1995 ; Moritani et al., 1996). 
 
Historically, Cnicus benedictus.L was used in the middle ages as a cure for bubonic 
plague with the main constituent, amaroidcninin. The amaroids are known to 
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stimulate the secretion of saliva and gastric juices. The herb has been used as anti-
diarrhoeal, antihaemorrhagic, expectorant and for wound healing (Bradley, 1992; 
Bisset, 1994; Chevalier, 2000; Van Wyk et al., 2004). The plant species has also been 
extensively used by traditional healers for anorexia, pain, flatulence, dyspepsia, 
diabetes, bronchial catarrh and topically for gangrenous and indolent ulcer (Bisset, 
1994; Van Wyk., 1997). 
 
Even though scientific evidence exists for some pharmacological activities such as 
the anti-inflammatory, antitumour and antimicrobial effects of the plant species, none 
has been found in any literature to corroborate the claim by traditional medicine 
practitioners of therapeutic success of the plant species in the treatment of diabetes 
and pain. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Overview of Diabetes mellitus 
 
2.1.1. Description 
 
Diabetes mellitus is a widely known chronic metabolic disorder characterized by 
deficiency of insulin secretion or the inability of the body to use effectively the 
insulin produced or a combination of these. Diabetes mellitus involves fat, 
carbohydrate and protein metabolism. The condition is generally divided into two 
main types, idiopathic and secondary. Idiopathic diabetes is classified as insulin 
dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus 
(NIDDM). IDDM, previously known as juvenile onset diabetes mellitus, is 
commonly called type 1 diabetes mellitus and NIDDM, previously known as adult 
onset diabetes mellitus is called type 2 diabetes mellitus. Despite that common 
classification, other types of diabetes such as pancreatic diabetes and gestational 
diabetes mellitus are also identified (Anon, 2010; World Health Organization 1999; 
Standard treatment guidelines, 2012; King, 2014) 
 
2.1.2. Pathophysiology and Pathogenesis of diabetes mellitus 
 
Type 1 diabetes mellitus 
 
Insulin is a polypeptide hormone known to regulate carbohydrate metabolism. It 
comes from the Latin word insula which means “island” because of its production by 
beta cells called Islets of Langerhans. Those cells are located in the pancreas. During 
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a meal, the food is transformed through the digestive system where nutrients, fats, 
proteins and carbohydrates are absorbed into the bloodstream. The presence of 
carbohydrates stimulates the pancreas to secrete insulin. Insulin works by enabling 
the entry of glucose from blood into muscles and other tissues where the glucose is 
metabolized for energy production. Deficiency of insulin secretion is the major defect 
in type 1 diabetes while type 2 diabetes has two main defects, insulin resistance and 
the impaired insulin secretion. (Anon, 2010)  
Type 1 diabetes develops when pancreatic beta cells are unable to produce insulin 
because of progressive destruction of beta cells. The process of beta-cell destruction 
starts when macrophages and dendritic cells present beta cell antigens to naive CD4+ 
T-cells through the major histocompatibility complex. Through a series of interleukin 
signaling, CD4+ T-cells are activated, which in turn activate CD8+ T-cells directly 
responsible for causing beta-cell death. The progressive autoimmune destruction of 
pancreatic beta cells results in deficiency of insulin secretion which leads to 
uncontrolled lipolysis and high levels of free fatty acids in plasma, causing metabolic 
disorders such as impaired glucose(increase of glucose concentration in the blood), 
protein, and lipid metabolism (Al Homsi et al., 1992; Yoon et al., 2005; Ahmad, 
2014; Ogbera, 2014; Ozougwu, 2013) 
Type 1diabetes mellitus is not only a result of autoimmune factors but also an 
interaction of genetic and environmental factors. The genes involve in type 1 diabetes 
are multiple but the most susceptible one is located on chromosome 6 specifically on 
the human leukocyte antigen (HLA) region of the chromosome. Polymorphisms 
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occurring in the HLA region increase the genetic risk of developing diabetes mellitus 
type 1 more, strongly individuals with genotyping showing the  haplotypes 
DQA1*0301, DQB1*0302, and DQB1*0201. (Ulbelen et al., 1977; Powers, 2015a)  
 
Type 2 diabetic mellitus 
In most cases, diabetes mellitus type 2 usually involves insulin resistance. Insulin is 
known to act by biding to its specific receptor on plasma membrane through a series 
of intracellular protein phosphorylation mechanisms that result in glucose uptake. 
Previously, insulin resistance was thought to be the main abnormality in type 2 
diabetes mellitus and that the inability to secrete insulin was a very late manifestation 
(Reaven et al., 1988). This concept has changed because scientific studies have 
shown that there is a feedback mechanism ensuring the integration of glucose 
homeostasis to maintain glucose concentration in a narrow range. This feedback 
regulation involves beta cells and insulin sensitivity (Kahn et al., 1993). Several 
studies show that insulin resistance precedes the defect in insulin secretion but 
individual will develop diabetes only when insulin secretion is inadequate to maintain 
glucose concentration close to normal (Triplittet al 2014; Khan et al., 2014). 
Type 2 diabetes mellitus is more characterized by a combination of various factors 
related to insulin resistance, relative deficiency or diminished effectiveness of insulin 
and environmental factors including obesity, over eating, sedentary lifestyle and 
stress (Kahn et al., 1993; Khan et al., 2014; Kaku, 2010). 
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2.1.3. Diagnosis 
 
The following criteria are applied to diagnose diabetes mellitus in patients: 
a) Patients with classic symptoms of diabetes mellitus, plus a random plasma 
glucose concentration at or above 11.1 mmol/L (200mg/dL). Random plasma 
glucose is defined as a glucose test done anytime of the day regardless of the 
time since the last meal consumption. (Anon, 2010; Standard treatment 
guidelines , 2014; Powers, 2015a). 
b) Fasting plasma glucose concentration at or above 7.0 mmol/L (126mg/dL) or 
fasting blood glucose at or above 6.1 mmol/L. 6.1. Fasting is defined as no 
caloric intake at least 8 hours before the test is performed. (Anon, 2010; 
Standard treatment guidelines , 2014; Powers, 2015a). 
c) 2 hours plasma glucose concentration at or above 11.1 mmol/L (200mg/dL) 
during an oral glucose tolerance test (OGTT). OGTT is performed according 
to the WHO description, using a 75 g of oral glucose load. (Anon, 2010; 
Standard treatment guidelines , 2014; Powers, 2015a). 
d) Glycated hemoglobinA1c test (HbA1C) at or above 6.5 % (≥0.065; ≥48 
mmol/molHb) which represent the percentage of haemoglobin that has 
glucose attached and should be performed in laboratory (Anon, 2010; Powers, 
2015a). 
 
2.1.4. Signs and symptoms 
 
Classic symptoms of diabetes mellitus are excess and frequent urination or polyuria, 
excessive hunger or polyphagia and excessive thirst or polydipsia. These symptoms 
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are more common in diabetes mellitus Type 1 compare to Type 2. The polyuria is 
characterized by increased plasma glucose concentrations exceeding the limit for 
glucose reabsorption in the kidney. As a result, glucose is spilled into the urine and 
creates a hyperosmolar environment causing patients to urinate more frequently. 
Excessive plasma glucose increases the chance of dehydration. In the attempt to 
correct this excess, hyperosmolar state and dehydration will stimulate excessive 
thirst. Finally, the excess plasma glucose cannot be used efficiently which results in 
lack of energy to be used by the body. In the attempts to correct the energy 
deficiency, the body will stimulate excessive eating (polyphagia). The most common 
symptom of diabetes mellitus Type 2 is fatigue followed by nocturia because 
symptoms of Type 2 diabetes occur more slowly (Standard treatment guidelines , 
2014 ) 
 
2.1.5. Screening 
 
Screening for diabetes mellitus Type 1 is recommended in high risk people while 
Type 2 is recommended in people with body mass index at or above 25 kg/m2 and 
experiencing at least one risk factor of Type 2 diabetes. The risk factors for 
developing diabetes mellitus Type 2 include: first degree family history of diabetes, 
physical inactivity, history of cardiovascular disease, hypertension and high 
triglycerides. Adults from the age of forty should be screened for diabetes even 
without any risk factors of developing diabetes Type 2 as age itself can be a risk 
factor for diabetes Type 2.(Standard treatment guidelines , 2012; Standard treatment 
guidelines , 2014; Herrier et al., 2015). 
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Children losing weight despite a good appetite, experiencing polyuria, polydipsia, 
tiredness, abdominal pain and a sweet smell on their breath with a positive ketones 
urine test should be screened for diabetes. Children above the age of 10 or with 
physical signs of puberty and experiencing hypertension, hyperlipidaemia, polycystic 
ovarian syndrome together with family history of diabetes and body mass index 
above 85 % for age and gender should be screened for diabetes. (Standard treatment 
guidelines , 2012; Standard treatment guidelines , 2014; Herrier et al., 2015). 
 
2.1.6. Clinical presentation 
 
Table 1 Clinical presentation of diabetes Mellitus Type 1 and 2 
 
Criteria Diabetes mellitus Type 1 Diabetes mellitus Type 2 
 
 
Age of onset 
Juvenile onset , commonly 
below age of 30 
Maturity onset, commonly 
above age of 30 
 
 
Body weight 
 
Non-obese 
Patients usually obese or have 
history of obesity 
 
Symptoms ( refer to 
signs and symptoms 
section) 
 
Symptomatic 
 
Often asymptomatic 
 
Insulin resistance 
 
Absent 
 
Present 
 
 
Acute complications 
 
Associated with diabetes 
ketoacidosis 
 
Associated with hyperosmolar 
hyperglycaemic state 
 
 
Insulin therapy 
 
Immediate after diagnosis 
 
Years later after diagnosis 
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2.1.7. Management of diabetes mellitus 
 
2.1.7.1. Non-drug therapy 
 
General measures for non-drug treatment include lifestyle changes, nutrition control 
and patient education. Patient education is an important key to maintain an ideal 
adherence to therapy. Patients should be advised to wear a disease identification 
bracelet, card or necklace in case of emergency assistance. Lifestyle changes focus on 
losing weight for overweight patients and also moderate physical exercises. Physical 
activity such as walking for 30 minutes for three days a week, climbing stairs etc are 
recommended (Standard treatment guidelines ,2014; Powers, 2015b). 
Diet control is more complex, patients should have a nutrition rich in fruit and 
vegetables and a low fat diet. The daily meal regimen should include only one fresh 
fruit at a time and the following:  
 One portion containing vitamin C such as cabbage family, guavas and 
tomatoes. 
 One portion of dark green vegetables such as green beans, baby marrow and 
broccoli. 
 One portion of dark yellow-orange vegetables such as pumpkin and carrots. 
 One fresh fruit at a time. 
 
Healthy diet including low fat dairy products such as two cups of milk daily for 
adults and limited consumption of cheese. It is preferable to eat chicken without skin 
and fish compared to red meat. Food containing high level of cholesterol and 
saturated fat should be restricted. Adequate fluid intake per day (women at least 4 
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glasses of 250 ml and men at least 6 glasses of 250 ml of water) and increase fibre 
consumption (Standard treatment guidelines ,2014; Powers, 2015b) 
 
2.1.7.2. Drug therapy 
Diabetes mellitus is a chronic condition difficult to cure but the management focuses 
on keeping the plasma glucose concentrations as close as possible to normal range 
with the help of glucose lowering medications, exercises and healthy nutrition. Target 
goals should be individualized with each patient after consultation with a medical 
practitioner. To reach the treatment goal, the HbA1c is the marker used to monitor 
patient glycaemia. The target HbA1c differs from young adult to elderly close to 
normoglycemia without significant hypoglycaemia. A key factor is patient education 
and understanding of the disease and complications associated with diabetes such as 
risks of cardiovascular disease. Treatment of diabetes depends on the type of 
diabetes. In general, Type 1 diabetes mellitus is caused by absence of insulin 
therefore; insulin should be administrated to a patient suffering with Type 1diabetes.  
Type 2diabetes is more characterized by insulin resistance and treatments include oral 
anti-diabetic medications (Standard treatment guidelines, 2014; Powers, 2015b; 
Triplitt et al., 2014). 
a) Insulin therapy 
Insulin is used for treatment of diabetes mellitus Type 1 and involve sadministration 
of combined split-mixed injections. It is also used in acute diabetes emergencies such 
as diabetic ketoacidosis (DKA) and pregnancy. It can be used as a supplement in 
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diabetes Type 2 when oral therapy fails to control blood glucose concentrations. The 
common adverse reactions observed with insulin therapy are hypoglycaemia and 
rebound hyperglycaemia. Hypoglycaemia can lead to brain damage. Usually, patients 
with chronic renal impairment required less insulin therefore, regular control of blood 
glucose levels must be done to minimize the risk of hypoglycaemia. Rebound 
hyperglycaemia also known as somogyi effect, occurs after an episode of 
hypoglycaemia following insulin administration especially at night. This is caused by 
release of counter regulatory hormones such as glucagon, adrenaline, cortisol and 
growth hormone. Currently, 4 types of insulin injections are available: rapid acting 
insulin, short acting insulin, intermediate acting insulin and long lasting insulin 
(Powers, 2015b; Triplitt et al., 2014).  
Rapid acting insulins 
They have a very fast onset of action that permits more replacement of physiologic 
prandial insulin. Their duration of action is short with less risk of hypoglycaemia 
after meal. Insulin aspart, insulin lispro and insulin glulisine are the three 
commercially used ones in this class. Insulin aspart is obtained from substitution of 
the B28 proline with aspartic acid and therefore, prevents insulin self-aggregation. 
Insulin lispro is formulated by exchanging the position of proline and lysine (Proline 
at B28 goes to B29 while lysine at B29 goes to B28) which permits a very low 
propensity compared to human insulin. Insulin glulisine is created from substitution 
of the B3 lysine with asparagine and the B29 lysine with glutamic acid (Powers, 
2015b; Triplitt et al., 2014). 
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Short acting insulins  
Recombinant DNA techniques are recent techniques used to produce short acting 
soluble insulin molecule very close to human insulin. Short acting soluble insulin is a 
regular insulin molecule which is administrated intravenously 30 to 45 minutes 
before meal. If given at meal time, short acting insulin can cause early postprandial 
hyperglycaemia and late postprandial hypoglycaemia. It is very useful in diabetic 
ketoacidosis management (Powers, 2015b; Triplitt et al., 2014). 
Intermediate acting and long lasting insulins 
 
Neutral protamine hagedorn (NPH) insulin, intermediate acting insulin regularly used 
in combination with rapid and regular insulins. NPH action is unpredictable therefore 
is used in combination with insulin analogs having predictable action. The morning 
administration of intermediate acting insulin provides basal insulin for the day and 
covers the midday meal whereas the evening dose covers basal insulin for the evening 
and the rest of the day. Glargine and detemir are long acting insulin providing 
peakless basal insulin lasting more than 20 hours. Insulin glargine is often 
administrated once a day but insulin resistant patients can have split dose (twice a 
day). Insulin detemir is the most recent developed insulin and has less risk of 
hypoglycaemia than NPH insulin (Powers, 2015b; Triplitt et al., 2014). 
b) Oral anti-diabetic drugs 
The main goal of the treatment is to reduce and maintain blood glucose 
concentrations close to normal range and for as long as possible, in order to prevent 
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complications associated with increase glucose concentrations in human body. Oral 
therapy is prescribed in Type 2 diabetes mellitus when diet alone has failed and also 
as an adjunct to continued diet restriction (Powers, 2015b; Triplitt et al., 2014; 
Sumrall et al., 2009). 
Biguanides 
Biguanides are known to reduce hepatic output of glucose and increase glucose 
uptake by peripheral muscle tissues. Commonly used drug is metformin with no 
direct effect on pancreatic beta cells. Metformin reduces endogenous insulin 
requirements but also reduces plasma triglycerides and LDL-C by 8 to 15%. Amongst 
other oral antidiabteic medications, metformin is useful in reducing macrovascular 
complication in obese patients and does not stimulate appetite or cause weight gain. 
Metformin reduces HbA1c level by 1.50 to 2.0%. Metformin can be used in 
combination with other oral antidiabetic drugs especially sulphonylureas. It is and 
usually given as the first line treatment for Type 2 diabetes mellitus in conjunction 
with lifestyle modification (such as weight loss or exercise). Metformin has no risk of 
serious hypoglycaemia but is associated with mild gastrointestinal side effects such as 
abdominal discomfort, diarrhoea and stomach upset. In order to reduce these side 
effects, the drug should be taken with meals or after meals. Metformin should be used 
with caution in patients suffering from impaired kidney or liver function. 
Hypoglycaemia is observed when metformin is used in combination with 
sulphonylureas (Powers, 2015b; Triplitt et al., 2014; Sumrall et al., 2009). 
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Sulphonylureas 
They are insulin secretagogues widely used as oral antihyperglycaemic drugs. They 
work by binding to sulfonylurea receptor on beta cell surface to stimulate secretion of 
insulin from the pancreatic beta cells. Sulphonylureas are divided into two groups, 1st 
generation and 2nd generation. Second generartion sulphonylureas have fewer side 
effects and are more effective than the first generation. First generation has a shorter 
duration of action compared to the second generation. Commonly used first 
generation drugs are tolazamide, tolbutamide, acetohexamide, and chlorpropamide. 
Commonly used second generation drugs are glibenclamide glimepiride, glipizide 
and gliclazide. They can be used as monotherapy or in combination with other 
antidiabetic drugs. Average reduction of HbA1c level by sulphonylueras is 1.50 to 
2.0%.  Drug interactions occur when given with drugs such as salicylates, warfarin or 
sulphonamides. Hypoglycaemia and weight gain are the most common side effects 
associated with sulphonylureas administration (Powers, 2015b; Triplitt et al., 2014; 
Sumrall et al., 2009). 
Alpha glucosidase inhibitors  
They do not have a direct effect on insulin sensitivity or insulin secretion but they act 
by competitively inhibiting α-glucosidase enzymes in the intestine. The inhibition 
causes a reduction in postmeal glucose excursions by slowing the digestion and 
absorption of starch in the small intestine. Acarbose is the most commonly used drug 
in this class. It inhibits carbohydrate digestion and lowers the postprandial glucose 
concentration by 30 to 50%. These drugs are useful as monotherapy in early stages of 
 
 
 
 
18 
 
impaired glucose tolerance but can also be used in combination with other 
antidiabetic drugs. These drugs reduce HbA1C level by 0.5 to 1.0%. The major side 
effects associated with this class of drugs are abdominal pain, flatulence and 
diarrhoea. Hypoglycaemia is observed when they are used in combination with 
sulphonylureas or insulin (Sumrall et al., 2009; Kennedy et al., 2015). 
Thiazolidinediones (TZDs) 
Pioglitazone and rosiglitazone are the two drugs currently used for diabetes mellitus 
Type 2. TZDs are referred as glitazones. They work by binding to the peroxisome 
proliferator activated receptor gamma (PPAR-γ), a type of nuclear regulatory protein 
found in fat, muscle and liver. These PPAR-γ receptors are involved in modulating 
the expression of the genes regulating insulin signal transduction and glucose and 
lipid metabolism. TZDs are used to improve insulin sensitivity, reduce cellular 
resistance and improve glycaemic control based on the adequate production of insulin 
by pancreatic beta cells. TZDs can be used as monotherapy or in combination with 
other oral antidiabetic medications.  TZDs reduce HbA1C level by 1.5 to 2.0%. The 
use of this class of drugs has been reduced due to safety concern and side effect 
shown by multiple retrospective studies. The result from forty two randomized 
clinical trials suggested an increased risk of myocardial infarction or angina pectoris 
associated with rosiglitazone administration. Some side effects associated with these 
drugs are fluid retention, heart failure, hypoglycaemia and liver injury. Combination 
of metformin with TZDs has the advantage of not causing hypoglycaemia (Sumrall et 
al., 2009; Kennedy et al., 2015). 
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Meglitinides 
They are non-sulphonylurea insulin secretagogues often called short acting 
secretagogues and are rapidely absorded. The commonly known drugs under this 
class are vateglinide and repaglinide. These drugs work by stimulating insulin 
secretion through interaction with potassium channels on pancreatic beta cells to 
boost insulin response after meal. These medications are given orally just before 
meals to compensate for the defect in insulin response after meal consumption and if 
a meal is skipped, the drugs should also be skipped. Repaglinide has a faster onset of 
action and more appropriate for controlling postprandial glucose excursion. 
Meglitinides reduce the HbA1c level by 0.5 to 1.0%. Both drugs can cause 
hypoglycaemia and weight gain as side effects but the risk of hypoglycamia is less 
compared to sulphonylureas (Triplitt et al., 2014). 
Incretin mimetics 
Incretins are gut hormones released to intensify the glucose induced insulin secretion. 
Glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide 
(GIP) are the major incretins involved in increased secretion of insulin. Diabetes 
mellitus Type 2 is more sensitive to GLP-1 compared to GIP because of the 
deficiency in GLP-1 levels in Type 2 whereas GIP levels are usually normal or high. 
GLP-1 infusion in diabetes Type 2 causes stimulation of insulin release and reduction 
of glucose concentrations. All GLP-1 receptor agonists can increase the risk of 
pancreatitis and patients are advised to seek medical care in case of severe abdominal 
pain after administration. GLP-1 agonists are not recommended to be used in patients 
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with family history or past medical history of Type 2 multiple endocrine neoplasia 
syndrome or medullar thyroid cancer (Triplitt et al., 2014; Sumarall et al., 2009; 
Kennedy et al., 2015). 
Exenatide is a GLP-1 agonist and the first one in this class of drugs to be approved 
for treatment of diabetes type 2. It is given as a fixed dose by subcutaneous injection 
within one hour before breakfast and dinner. Exenatide used in mono or combined 
therapy reduces the HbA1c by 0.2 to 1.2%. The common side effect is nausea and the 
drug is contraindicated in patient with glucose filtration rate below 30 ml/min 
(Triplitt et al., 2014; Sumarall et al., 2009; Kennedy et al., 2015). 
Pramlintide is a soluble and non-aggregating peptide analogue of human amylin and 
administrated subcutaneously twice daily in Type 1 and Type 2 diabetes patients 
unable to reach their targeting postprandial blood glucose concentrations. The drug is 
given immediately before eating and reduces A1C in diabetes Type 1 by 0.1 to 0.4 % 
and in Type 2 by 0.3 to 0.7%. The side effects include hypoglycaemia, anorexia, 
nausea, and vomiting. The drug is contraindicated in patients suffering from 
gastroparesis (Triplitt et al., 2014; Sumarall et al., 2009; Kennedy et al., 2015). 
Liraglutide is a GLP-1 agonist analogue (97% homology to GLP-1) which increased 
glucose dependent insulin secretion and reduced the high glucagon secretion in 
presence of increased blood glucose levels. It is administered once daily in diabetes 
mellitus Type 2 concurrently with metformin, TZDS or sulphonylureas 
administration. Liraglutide reduces HbA1c level by 0.8 to 1.50% with nausea and 
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vomiting as the most common side effects (Triplitt et al., 2014; Sumarall et al., 2009; 
Kennedy et al., 2015). 
Dipeptidyl peptidase-4 (DPP-4) inhibitors 
They are called incretin enhancers as they increase the blood concentration of GLP-1 
and prolong its half-life by preventing the natural breakdown of incretins by DDP-4. 
The examples of DDP-4 inhibitors approved in the United States are linapliptin, 
sitagliptin and saxagliptin. The average reduction of the HbA1C level by DPP-4 is 
around 0.7 to 1%. Incretin enhancers are very well tolerated. They do not increase the 
risk of hypoglycaemia and do not cause gastrointestinal disturbances (Triplitt et al., 
2014; Sumarall et al., 2009). 
Bile acid sequestrants 
Colesevelam is the only one drug in this class to be approved for treatment of 
diabetes mellitus Type 2. Colesevelam is a cholesterol lowering medication also used 
as an antihyperglycemic agent that works by binding to the bile acid in the lumen of 
the intestine resulting in reduction of the bile acid. Colesevelam reduces the HbA1C 
by 0.3 to 0.5%. Some side effects occurring with colesevelam administration include 
constipation, indigestion and dyspepsia. The drug is contraindicated in patients with 
past medical history of major gastrointestinal surgery and those suffering from 
gastroparesis and bowel obstruction (Kaku, 2010; Kennedy et al., 2015). 
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Dopamine agonists 
Bromocriptine mesylate is the dopamine agonist in this class currently approved to be 
used in treatment of diabetes mellitus Type 2. The mechanism of action of 
bromocriptine is not yet clear but the drug improves the glycaemic control and 
hepatic insulin sensitivity. The drug reduces the HbA1C level by 0.3 to 0.6% from 
baseline. The side effects include fatigue, vomiting, nausea, dizziness and headache 
(Triplitt et al., 2014; Kennedy et al., 2015). 
 
c) Combined therapy in diabetes mellitus Type 2 
Failure to maintain good glucose concentrations despite monotherapy for long term 
treatment may require multiple medications to achieve glycaemic control. Diabetic 
Type 2 treatment usually starts with metformin unless there is a contraindication. In 
the case of clinical failure with metformin, a second agent is added. Second agents 
include sulphonylureas, pioglitazone, DDP-4 inhibitors, GLP-1 receptor agonists, 
SGLT2 inhibitors and insulin. Before adding the second agent, considerations are 
given to efficacy of the agent, risk of hypoglycaemic, weight gain, side effects and 
cost. Insulin therapy is introduced when oral agents combined with injectable GLP-1 
receptor agonists fail to maintain reasonable glucose concentrations. If two agents 
still can’t maintain a good response to therapy, a third agent cannot be added 
(Kennedy et al., 2015). 
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2.1.8. Monitoring 
 
The rate of mortality and morbidity related to diabetes mellitus can be significantly 
reduced by consistent monitoring of the treatment therefore, decreasing the risk of 
complications associated with diabetes. Patients need to receive a comprehensive 
education of the condition including nutrition, regular exercise and therapeutic 
regimen. For optimal diabetic care, continuous self-monitoring of blood glucose 
levels is required together with a long term glycemic control by a medical 
practitioner. Blood glucose levels should be perfectly monitored at home in patients 
receiving more than two doses of insulin per day. Patients who meet treatment targets 
should have an annual HbA1c test whereas patients whose treatment has changed 
need the test every 3 to 6 months. Each hospital visit should take into account the 
weight and blood pressure of patients. An annual examination of potassium, lipids 
and creatinine must be done. Depending on the dilatation of the pupils, a fundoscopy 
must be done annually (Standard treatment guidelines, 2014; Powers, 2015b)  
 
2.1.9. Complications 
 
Diabetes mellitus can lead to acute and chronic complications affecting several organ 
systems. Acute complications of diabetes include hypoglycaemia and hyperosmolar 
hyperglycaemicnon-ketotic syndrome. Chronic complications related to diabetes are 
divided into two main groups, nonvascular and vascular complications. The 
nonvascular complications include conditions such as hearing loss, gastroparesis, 
infections and skin changes. The vascular complications are divided into 
microvascular and macrovascular complications. The microvascular complications 
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result from chronic hyperglycaemia and include neuropathy, retinopathy and 
nephropathy diseases. Retinopathy may cause blindness while nephropathy may lead 
to renal failure. Diabetes neuropathies play an important role in mortality and 
morbidity related to diabetes. Hyperglycaemia also leads to impairment of white 
blood cell function and complication of wound healing which may result in 
amputation of the lower limb. Rigorous glycaemic control can reduce the risk of 
microvascular complications.The macrovascular complications include peripheral 
vascular disease, atheroma, high blood pressure, coronary artery disease, myocardial 
infarction, obesity and hyperlipidemia (Triplitt et al., 2014; Powers, 2015b; Standard 
treatment guidelines , 2012). 
 
2.1.10. Diabetes emergencies 
2.1.10.1. Diabetes ketoacidosis (DKA) 
 
DKA is a diabetic emergency and life threatening condition often precipitated by 
increased insulin demands. It often occurs in younger people and developed over 
hours to days. DKA is caused by insulin omission, inadequate administration of 
insulin and intercurrent diseases such as pancreatitis or myocardial infarction. It 
usually occurs in diabetes mellitus Type 1 when cells in the body cannot get the 
glucose they need for energy. In normal situation, cells in the body need glucose to 
produce the energy they need. Insulin enables glucose (sugar) entry from blood into 
muscles and other tissues. In case of insulin deficiency, the body is unable to use 
glucose for energy needed. In order to produce energy, the body starts to breakdown 
fat and proteins leading to production of ketones and free fatty acids.  The produced 
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ketone and fatty acids enter the bloodstream causing chemical imbalance (metabolic 
acidosis) called diabetic ketoacidosis. Severe ketoacidosis can cause breathing 
difficulties, brain swelling, increased risk of coma and even death (Triplitt et al., 
2014; Powers, 2015b).  
Symptoms 
The symptoms of DKA include strong fruity breath odour, blurred vision, drowsiness, 
confusion, dry skin, loss of appetite and vomiting. These symptoms are often noticed 
only after a very high level of blood sugar. Patients present with glucose level usually 
higher than 40 mmol /L, a serum osmolality greater than 350 mosm /L and a positive 
blood ketones test (Triplitt et al., 2014; Powers, 2015b). 
Treatment 
The goal treatment is to stabilize the patient at glucose levels around 8.3 to 13.9 
mmol /L (150 to 250 mg /dL) and resolved the acidosis state. 
 Oral or intravenous fluid replacement to dilute the increased blood glucose 
and rehydrate the body (too much fluid lost through excessive urination). 
 Electrolyte replacement to maintain muscle, nerve and heart. Electrolytes are 
measured (particularly potassium, bicarbonate and phosphate) every 4 hours 
for the first 24 hours particularly. 
 Intravenous insulin therapy to reverse DKA until the blood becomes non 
acidic. Insulin is administrated only after potassium level is corrected. 
Close monitoring of blood pressure, respiration, pulse, mental state and fluid intake is 
required every 1 to 4 hours (Triplitt et al., 2014; Powers, 2015b). 
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2.1.10.2. Hyperosmolar nonketotic diabetic coma (HONK) 
 
Hyperglycaemic hyperosmolar state is a syndrome that usually occurs in elderly 
people with diabetes mellitus Type 2. It can also appear in younger diabetic patients 
presenting with serious renal insufficiency or prolonged hyperglycemia and 
dehydration. The underlying causes are insufficient fluid intake and relative insulin 
deficiency (Powers, 2015c; Standard treatment guidelines , 2012)  
 
Symptoms 
Patients present with impaired consciousness, extreme dehydration and severe 
hyperglycaemia not accompanied by severe ketoacidosis. The condition develops 
over days to weeks with blood glucose level greater than 40 mmol/L, serum 
osmolality higher than 320 mOsm/L and blood ketone test usually negative to slightly 
elevated. Ketonemia and acidosis are rarely present but a small quantity of anion gap 
metabolite may be present (Powers, 2015c; Standard treatment guidelines , 2012).  
 
Treatment 
Fluid replacement is the first step to stabilize the hemodynamic status and reverse the 
hyperosmolar state as dehydration and fluid loss are more pronounced compared to 
DKA. Patient’s fluid must be closely monitored and electrolyte replacement is also 
required. Intravenous insulin therapy is necessary (Powers, 2015c; Standard treatment 
guidelines , 2012). 
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2.1.11. Other types of diabetes 
 
2.1.11.1. Gestational diabetes 
 
According to Harrison’s principles of internal medicinal, 4% of pregnant women 
develop gestational diabetes. Glucose tolerance occurring during pregnancy is usually 
categorized as gestational diabetes whereas insulin resistance is related to the 
metabolic changes affecting the body during late pregnancy (Powers, 2015a; Barbieri 
et al., 2015). 
In attempts to maintain glucose concentration in normal ranges, the body increases 
the insulin secretion but increased insulin may lead to impaired glucose tolerance or 
diabetes. Gestational diabetes increases the risk of preeclampsia, stillbirth and 
delivery complication due to baby weight. Assessment of risks of developing 
gestational diabetes should take placeduring the first prenatal visit. However, these 
risks can be reduced by close monitoring of blood glucose through the whole 
pregnancy. The diagnosis is done with 75 g of oral glucose tolerance test (OGTT) at 
24 to 28 weeks of gestation and applying the following criteria: 
 Fasting plasma glucose test greater or at 92 mg /dL (5.1 mmol /L) 
 1 hour  plasma glucose test greater or at 180 mg /dL (10 mmol /L) 
 2 hours plasma glucose test greater or at 153 mg /dL ( 8.5 mmol /L) 
Gestational diabetes mellitus is confirmed when patients meet any one of the 
diagnosis criteria listed above. In the event where diabetes is diagnosed before 
pregnancy, this is not classified as gestational diabetes but rather as pregnancy with 
pre-existing diabetes mellitus (Triplitt et al., 2014; Barbieri et al., 2015). 
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2.1.12. Summary of streptozotocin-induced diabetes 
 
Streptozotocin (STZ) is one of the most prominent cytotoxic glucose analogue used 
in diabetic research.  STZ is an antimicrobial agent with diabetogenic properties and 
also used as an alkylating agent in chemotheray.  The effects of STZ on insulin and 
blood glucose concentrations reflect its toxic induced abnormalities in beta cell 
functions. The low affinity of GLUT2 glucose transport in the plasma membrane 
causes STZ to be selectively accumulated in the pancreatic beta cells resulting in 
inhibition of insulin secretion (Schein et al., 1967; Rakieten et al., 1963; Bergevin, et 
al., 1974). In the present study, streptozotocin (STZ) was used to induce diabetes in 
rats. 
Table 1: Summary of chemical characteristics of streptozotocin (Lenzen et al., 2008) 
 Chemical Characteristics  of Streptozotocin 
 
Chemical 
name 
 
2-Deoxy-2-([(methylnitrosoamino)carbonyl]amino)-D-glucopyranose 
 
Chemical 
structure 
 
It has a cytotoxic methylnitrosourea moiety (Nmethyl-N-nitrosourea) 
attached to the glucose (2 deoxyglucose) molecule; glucosamine 
derivative ( see figure below) 
 
 
Chemical 
properties 
 
Hydrophilic, beta cell-toxic glucose analogue. 
It is relatively stable at pH 7.4 and 37OC (at least for up to 1 h) 
 
 
Chemical 
reactivities 
 
 
DNA alkylating agent and protein alkylating agent 
Toxicity 
mode 
DNA alkylation 
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Figure 1: Chemical structure of STZ( Lenzen et al., 2008) 
 
2.2. Overview of nociception and pain 
 
2.2.1. Description 
 
Pain can be described as an unpleasant complex sensation caused by tissue damage 
that leads to breakdown of cells followed by the release of biochemical substances 
that provoke autonomic responses. Nociception can be defined as the mechanism by 
which noxious peripheral stimuli are transmitted to the CNS (central nervous system). 
Pain is a subjective experience not always associated with nociception and involves 
strong emotional components whereas nociception is the perception of noxious 
stimuli (Li et al., 2015; Berry et al., 2009).  
 
Considering the symptoms presented, pain can be classified as acute, chronic and 
cancer pain. Acute pain is a physiologic process often nociceptive in nature and 
warning individuals of possible disease or potential harmful situations. If not treated 
or undertreated, acute pain can develop in to chronic pain development. Chronic pain 
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is usually a result of changes occurring in the nerve function and transmission 
therefore, making it difficult to treat. Pain associated with high risk of life threatening 
conditions is often referred to as malignant pain or as cancer pain in the case of 
cancer.  This type of pain sometimes has several aetiologies and comes from the 
disease itself. The pain includes components of both chronic and acute pain (Hanley 
et al., 2007; Latremoliere et al., 2009; Berry et al., 2006) 
 
The nature of pain varies and the amount of pain produced by a particular stimulus 
depends on several factors than the stimulus itself. Pain arising from joints, 
connective tissue of the skin, muscles and bones injury (somatic pain) is usually 
described as aching, sharp, throbbing and well localized. Pain arising from internal 
organs, gastrointestinal tract, stomach, liver and pancreas (visceral pain) is usually 
described as dull, cramping, deep, stabbing and sometimes diffuse. Pain arising from 
damaged peripheral or central nerves is usually described as tingling and burning (Li 
et al., 2015; Baumann et al., 2014). 
 
Nociception is well explained in terms of transduction, transmission, perception and 
modulation. Transduction can be summarized as the activation of receptors (known as 
nociceptors) by conversion of noxious stimuli into electrical activity. Noxious stimuli 
are activated by mechanical, chemical or thermal impulses. After receptor activation, 
the action potentials are transmitted along A-δ and C-afferent nerve fibres and this is 
known as nociceptive transmission. Stimulation of the A-δ afferent nerve fibres 
conveys well localized pain whereas stimulation of the C-afferent nerve fibre conveys 
a poor localized pain. The action potentials along afferent nerves are transmitted to 
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the spinal cord where the pain can be processed further. At that point, the pain 
becomes a conscious experience taking place in higher cortical components. 
Physiology around the perception of pain is complex and not well understood but 
associated with behaviours and cognitive functions. Modulation of pain is done by 
the body through several complex systems such as endogenous opiate systems (Li et 
al., 2015; Baumann et al., 2014; Berry et al., 2006). 
 
2.2.2. Pain management 
 
2.2.2.1. Non pharmacological therapy 
 
Some of the non-pharmacological therapies have been found to be useful in acute and 
chronic pain such as massage, application of cold or heat, relaxation, acupuncture, 
cognitive behavioural therapy, exercise and physical manipulation. Patient education 
about expected discomfort after certain medical procedures can reduce patient’s 
distress (Baumann et al., 2014; Chou et al., 2007; Benzon et al 2008; Simpson et al., 
2009). 
 
2.2.2.2.Pharmacological therapy (Analgesics) 
 
a) Non-steroidal anti-inflammatory Analgesics/drugs (NSAIDs) 
NSAIDs are used for somatic pain and in the treatment of pain due to inflammatory 
response. Common examples are acetylsalicylic acid (known as aspirin), 
indomethacin, ibuprofen, diclofenac and naproxen. Aspirin is contra-indicated in 
children with symptoms of flu. Aspirin used particularly in children presenting with 
symptoms of flu caused by virus can lead to Reye’s syndrome. This syndrome is 
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characterized by hepatic failure and encephalopathy (Baumann et al., 2014; Roelofs 
et al., 2008).  
NSAIDs work on central and peripheral systems to relieve pain by inhibiting the 
prostaglandins synthesis by blocking the activity of cyclooxygenase enzymes.  They 
are more effective in mild to moderate somatic pain compared to visceral pain 
(Baumann et al., 2014;Li et al ., 2015).  
 
b) Non opioid analgesics 
These agents are used in the treatment of mild to moderate somatic pain. 
Acetaminophen (known as paracetamol), is commonly used as first line treatment. 
Acetaminophen has both analgesic and antipyretic actions but also produced very 
little and no significant anti-inflammatory effects. The mechanism of action regarding 
its analgesic property is not well understood. Paracetamol produces its antipyretic 
effect by acting as a prostaglandin synthesis inhibitor in the brain with. It has fewer 
adverse effects when administrated in recommended doses. However, in higher doses 
it may cause nephrotoxicity, hepatotoxicity and thrombocytopenia. (Baumann et 
al.,2014; Li et al., 2015). 
 
c) Opioid analgesics 
Any substances whether endogenous or synthetic producing morphine like effects and 
antagonized by narcotic antagonists are referred to opioids. Opioid analgesics include 
both natural and semi synthetic alkaloid derivatives (from opium) and synthetic 
forms. They are classified as second line treatment in acute pain, chronic pain and 
cancer related pain. Opioids are used for pain treatment of any type or duration but 
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they are most effective in nociceptive pain.  There is no pharmacological dose but the 
dose depends on side effects and patient’s response. The side effects can be reversed 
with administration of narcotic antagonist such as naloxone. Opioids are generally 
divided into three main groups. The first group includes strong opioid analgesics used 
for severe painful conditions such as visceral and chronic pain. Common examples of 
strong opioids are diamorphine (Heroin), morphine, methadone and pethidine. Heroin 
is not used clinically. The second group includes mild to moderate opioid analgesics 
used in mild to moderate pain especially when the patient is not responding to 
paracetamol or aspirin. Some examples of second group are codeine, 
dextropropoxyphene and dihydrocodeine. The third group includes mixed agonist and 
antagonist (partial) opioid analgesics used to produce analgesia in severe pain. In this 
group, the drugs were initially developed as antagonists but when administrated 
alone, they produced effects similar to morphine effect but with less analgesic 
potency compared to morphine (Baumann et al., 2014; Li et al., 2015). 
 
2.3. Overview of Cnicus benedictus.L 
 
2.3.1. Description ofCnicus benedictus.L 
 
Cinicus benedictus, a plant commonly known as Bitter Thistle, Blessed Thistle, Holy 
Thistle, Spotted Thistle or St. Benedict's Thistle, is a thistle like plant belonging to 
the family Asteraceae and grows annually (Van Wyk et al., 2004; Llyod et al., 1983). 
C.benedictus usually grows to 30 to 50cm high but can also grow up to 70cm. The 
plant has a strong bitter taste. The stems are heavily branching and thistle-like, and 
 
 
 
 
34 
 
the leaves are amplexicaul with irregular teeth having wavy margin ending in spines. 
The upper leaves are sessile while the lower ones are petioled (Van Wyk et al., 2004; 
Lloyd et al., 1983; Vogel, 2005)  
 
Figure 2 : Picture of Cnicus Benedictushttp://www.uniprot.org/taxonomy/50282 
 
 
2.3.2. Origin and distribution 
 
C. benedictus.L originated in the Mediterranean region and has been introduced in 
most parts of Europe, South Africa and Central and South America. The word 
‘thistle’ comes from the old nomenclature under which the plant was formerly 
classified and ‘blessed’ refers to the healing powers of the plant while ‘Cnicus’ refers 
to the plant’s thorns and derived from the Greek word, Knizein meaning ‘to torment’. 
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. In South Africa C.benedictus is known locally as Karmedick in Afrikaans (Van 
Wyk et al., 2004; Lloyd et al., 1983; Vogel, 2005). 
 
2.3.3. Uses and properties 
 
C. benedictus is used to treat several ailments such as cancers, gout, diabetes and also 
applied externally to wounds and ulcers. The plant is mainly used as a bitter tonic and 
stomachic to treat dyspepsia and lack of appetite. The recorded uses in South Africa 
include the treatment of internal cancers, diabetes, arthritis and pain (Chevalier, 2000; 
Schneider et al., 1987; Van Wyk et al., 2004; Bisset et al., 1994; Natural Standard 
Monograph, 2008)  
 
2.3.4. Preparation and dosage 
 
C. benedictus is used as comminute drug and dried extract for infusion as tincture, 
liquid extract or tea. The tea is prepared by pouring 150 ml boiling water over 1.5 to 2 
gm of drug, allowing the drug to set for 5 to 10 minutes. The aromatic bitter dosage is 
given as 1 cup ½ hour before meals. One cup of tea is taken three times daily (Van 
Wyk et al., 2004; Chevalier, 2000; Bradley, 1992; Llyod et al., 1983). C.benedictus is 
the component of several herbal teas. 
 
2.3.5. Constituent of the plant 
 
Cnicus benedictus.L is mainly composed of the principal bitter constituents, 
sesquiterpene lactone glycosides of the garmacrane type from which the chief 
component is cnicin (0.2-0.7%). The constituents listed below also are part of the 
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plant species and are believed to contribute to the pharmacological activity of the 
plant. (Van Wyk et al., 2004; Chevalier, 2000) 
a) Salonitenolide and artemisiifolin (Van Wyk et al., 2004; Vanhaelen-Fastre, 
1974; Chevalier, 2000; Natural Standard Monograph, 2008; Bradley, 1992) 
b) Lignans which are known to contribute to the bitter charachteristics of the 
plants; arctigenin, trachelogenin, nortracheloside, several polyacetylenes and 
2-acetyl nortracheloside (Vanhaelen-Fastre, 1972; Van Wyk et al., 2004; 
Natural Standard Monograph, 2008) 
c) Triterpenoids such as α-amyrenone, α-amyrin, acetate,α-amyrin, 
multiflorenol,  multiflorenol acetate and oleanolic acid (Ulbelen et al., 1997). 
d) Flavonoids such as apigenin-7-O-glucoside, luteolinl and astragalin. (Ulbelen 
et al., 1997). 
e) Essential/volatile oils (0.3 %) such as p-cymene, citronellol, cuminal, 
fenchon, cinnamaldehyde and benzaldehyde) (Van Wyk et al., 2004; 
Chevalier, 2000; Natural Standard Monograph, 2008; Vanhaelen-Fastre, 
1973).  
f) Tannins (8%); phytosterols such as n-nanocosan,stigmasterol. (Van Wyk et 
al., 2004;).  
 
2.3.6. Pharmacological effects 
 
C C.benedictus is known to have pharmacological activities such as antimicrobial, 
anti-inflammatory and antiproliferative effects proven with animal studies but no 
clinical outcomes have been published. The antimicrobial activity was proven against 
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bacillus subtilis, brucella species, escherichia coli, proteus species, streptococcus 
faecalis, staphylococcus aureus and pseudomonas aeruginosa due to the presence of 
sesquiterpene lactone cnicin. (Vanhaelen-Fastre, 1968; Mascolo et al., 1987; Ryu et 
al., 1996; Vanhaelen-Fastre, 1972). 
In animal tests, cnicin shows some cytotoxicity in cell cultures and antitumor activity 
in mice. Use as an aromatic bitter, the plant is believed to increase the secretion of 
gastric juice and saliva and therefore increases appetite (Vanhaelen-Fastre, 1968; Van 
Wyk et al., 2004). 
2.3.7. Contra-indications 
 
C. benedictus is contraindicated during pregnancy due to its potential emmenagogue 
and abortifacient properties (Chevalier, 2000; Natural Standard Monograph, 2008). 
The plant is used traditionally to stimulate lactation but currently, this use is no 
longer recommended (Natural Standard Monograph, 2008). The plant is believed to 
increase GIT secretions and therefore, should be used with caution in cases of peptic 
ulcer (Chevalier, 2000; Natural Standard Monograph, 2008). The toxicity studies 
show that the plant given in large doses greater than 5 g per cup of tea may cause 
vomiting (Chevalier, 2000; Vogel, 2005; Natural Standard Monograph, 2008). 
 
2.4. Description and objectives of the project. 
 
Several approved orthodox medicines around the world have been used to manage 
and treat different kind of ailments. However, various medicinal plants have also 
been used by traditional practitioners to provide remedies for these ailments 
especially in rural communities in developing countries. Therefore, the need arises 
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for the use of alternate medicines which can be easily available, accessible, cheap and 
relatively safe. Traditional medicines viz-a viz plant medicines have in the past been 
the major source of drug development. Plant medicines now have wide usage 
worldwide especially in rural communities of developing countries. The major 
problem often associated with this type of medicine is that of lack of scientific proof 
of their effectiveness in therapy. This, therefore, motivated the present study on the 
antidiabetic and antinociceptive activities of cnicus benedictus L. the plant species is 
used by traditional medicine practitioners to treat cancers, arthritis, diabetes, ulcer, 
pain and so on. It has been more than 150 years that Cnicus benedictus was 
introduced to South Africa. Since then, the plant has become a weed in the Cape and 
on the Highveld. However, there is little or no scientific evidence in literature to 
corroborate the claims made by traditional practitioners regarding the therapeutic 
successes of the plant species in the treatment of various ailments particularly 
diabetes and headache. Diabetes and painful conditions such as headache have been 
well managed with orthodox medicines as mentioned above. However, evidences 
abound to show that these medicines have problems of side effects which may 
encourage non-compliance by some patients therefore, worsening their conditions. 
Secondly, there have been instances of treatment failure with some orthodox 
medicines. 
Therefore, the present study intended to  
 Verify and validate mainly the antidiabetic activity of C.benedictus.  
 Verify the antinociceptive activity  
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 Investigate the acute toxicity in order to determine the safety profile of 
C.benedictus. 
 Carry out HPLC study in an attempt to characterize the plant species. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1. Plant materials 
 
3.1.1. Selection, collection and identification of plant material 
 
Cnicus benedictus.L was selected based on therapeutic claims made by traditional 
healers of its useful antidiabetic activities. The plant was bought from Montague 
museum, Cape Town, South Africa. The plant species was authenticated by a 
taxonomist in the Department of Biodiversity and Conservative Biology, University 
of the Western Cape. Voucher specimen of the plant (CNI) was deposited in the 
Herbarium of the University of the Western Cape. 
 
3.1.2. Preparation of leaf methanol extract of Cnicus benedictus.L 
 
Fresh leaves of the plant species (5.86kg) were washed with water and sliced into 
pieces before been dried in a ventilated oven at 35°C for 48 h. The dried plant 
material (3.44 kg) was ground into fine powder using a Warning Commercial 
Laboratory blender and a yield of 705 g was obtained. In order to prepare the 
methanol extract, 90 g of the dried powder was extracted in a soxhlet extractor with 
methanol as a solvent for 36 h. The methanol filtrate was evaporated to dryness using 
a Buchi RE IIrotavapor and Buchi 461 water bath. A yield of 11.4 g of crude 
methanol extract was obtained and preserved in a desiccator until further use. On 
each day of the experiment, fresh solution of the crude leaf methanol extract was 
prepared by dissolving weighed quantity of the methanol extract in a small volume of 
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dimethyl sulfoxide (DMSO) and made up to the appropriate volume with 
physiological saline. Methanol extract solution was administered intraperitoneally 
(i.p.) to mice and rats in a volume of 1 ml/100 g of body weight. 
 
3.2. Experimental animals 
 
Male and female albino mice weighing 10-30 g were used for the acute toxicity 
studies and antinociceptive evaluation of the leaf methanol plant extract. Healthy 
young adult Wistar rats of both sexes weighing 200-300 g were used for the 
assessment of the antidiabetic activity. All animals were bred in the Animal House of 
the Discipline of Pharmacology, University of the Western Cape, South Africa and 
kept in perspex transparent mouse or rate cages. They had access to food (standard 
pellet diet) and water ad libitum. The animals were housed in a quiet laboratory with 
an ambient temperature of 22 ± 2 °C and a 12 h light/12 h dark cycle was maintained. 
Animals were fasted for 16 h but still allowed free access to water prior to the 
commencement of the experiments and each animal was used for one experiment 
only.  
 
3.3. Drugs and chemicals 
 
Streptozotocin (STZ, Sigma Chemical Co) was dissolved in a small volume of 
sterile citrate buffer (pH 4.6, 0.1M) and made up to the appropriate volume with 
physiological saline. 
Chlorpropamide (Sigma Co.) was dissolved in physiological saline to an appropriate 
volume and given orally to rats using a bulbed steel needle.  
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Indomethacin (Sigma Chemical Co) was dissolved in a minimum volume of 
dimethylsulfoxide (DMSO, Sigma Chemical Co.) and adjusted to the appropriate 
volume with physiological saline. 
Paracetamol (4-Acetamidophenol, Sigma Chemical Co.) was dissolved in a 
minimum amount of propylene glycol and made up to an appropriate volume with 
physiological saline. 
Morphine sulfate (Bodene) was dissolved in physiological saline to the appropriate 
volume. 
Acetic acid (Merck) was dissolved in physiological saline to an appropriate strength. 
DMSO solution was prepared by dissolving an equal amount of DMSO used to 
dissolve the plant extract, in an appropriate volume of physiological saline. 
STZ, indomethacin, paracetamol, morphine, acetic acid and DMSO were 
administered intraperitoneally (i.p) to the animals. Acetic acid was administrated in a 
volume of 0.25 ml to mice. Fresh drug solutions were prepared each morning of the 
experiment. All drugs were administered in a volume of 1 ml/100 g of body weight of 
animals while constant volumes of DMSO, physiological saline and acetic acid were 
used. 
In each set of experiments, the control animals received equal volume injections of 
the appropriate vehicles. The doses and pre-treatment times of the leaf methanol 
extract of C.benedictus, and the standard drugs and the vehicles used were obtained 
from preliminary studies conducted in our laboratory; and also from similar studies 
(Amabeoku et al, 2011) 
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3.4. Acute toxicity 
 
The method described by Lorke (1983) and modified by El Hilaly et al. (2004) was 
used to determine the median lethal dose (LD50) of leaf methanol extract of Cnicus 
benedictus. Mice used were fasted for 16 hours prior to the commencement of the 
experiment and randomly divided into groups of 4 per cage. Graded doses of the plant 
extract in ascending order (100, 200, 400,600, 800, 1600, 2000, 2400, 2800, 3200, 
3600 and 4000 mg/kg) were separately administered orally to mice in each test group 
by means of a bulbed steel needle. Another group of 4 mice used as control, received 
0.3 ml of physiological saline orally each using a bulbed steel needle. The mice in 
both the test and control groups were then allowed free access to food and water and 
observed over a period of 5 days for death or acute toxicity symptoms. The median 
lethal dose (LD50) of leaf methanol extract of C.benedictus would be determined 
from the log dose-response plots constructed for the extract.  
 
3.5.High Performance Liquid Chromatography (HPLC) analysis 
 
Chromatographic system: Agilent 1200 system consisting of degassing system, 
quaternary pump, auto loading sampler, thermos statted column compartment, diode 
array detector, fluorescence detector, analyte fraction collector and Agilent 
ChemStation software ; column: Phenomenex Luna (C18) 5μm and dimensions (250 
cm x 4.6 mm). 
Chromatographic conditions: Mobile phase degassed with helium, solvent A: water 
containing 0.1% formic acid; solvent B: Acetonitrile containing 0.1% formic acid, 
Mode: flow rate, 0.8 ml/min; injection volume, 50 μl, detector, UV at 370 nm. The 
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eluent was monitored at several wavelengths ranged from 210 to 370 nm, the specific 
wavelength of interest being 350 nm. The HPLC operating conditions were 
programmed to give the following: 0 min, solvent B: 18%; 15 min, solvent B: 25%; 
20 min, solvent B: 35%, 30 min, solvent B: 90%. The run rate was 30 min. 
 
3.6. Pharmacological assessment 
 
3.6.1. Assessment of antidiabetic activity 
 
Modified method of Williamson et al. (1996) and Joy and Kuttara (1999) were used 
to assess antidiabetic activity in normoglycaemic rats and STZ-diabetic rats. 
 
3.6.1.1.Normoglycaemic rats 
The rats were randomly divided into seven groups of 6 each. The control group of 
fasted rats was treated with 0.3 ml of physiological saline administered orally. Four 
test groups of fasted rats were treated with intraperitoneal injections of leaf methanol 
extract of the plant species; one dose per group (50,100, 200, 400 mg/kg). The 
reference group of fasted rats was treated with chlorpropamide 250 mg/kg 
administered orally. The last group of fasted rats was treated with DMSO 
(0.25ml,i.p). The collection of blood samples was done from the tail vein of animals 
and measured by means of a glucometer. The blood glucose concentrations of 
normoglycaemic rats at the end of the 16 h fasting period were measured and 
considered as zero time (0 h) which was the time before treatment. After treatment, 
the blood glucose concentrations in each group were measured and recorded every 30 
min over 4 hours. 
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3.6.1.2. Induction of diabetes mellitus 
 
The modified method of Williamson et al. (1996) was used to induce diabetes in rats. 
A group of 6 rats were used in this experiment. A single dose of streptozotocin (STZ, 
80 mg/kg) in sterile citrate buffer was administrated to fasted rats by intraperitoneal 
injections. Following the injection, diabetes was allowed to develop and stabilize in 
rats over a period of 5 to 7 days. Then, plasma glucose was measured to confirm the 
diabetic state. The blood glucose measurement was obtained by pricking of the rat tail 
tip vein. A drop of blood was placed on a glucose test strip and the glucose 
concentrations were determined by using a compatible Glucometer (Accu-
Check®Abbot laboratory). Each glucose test strip was used only for one reading. 
Fasted STZ-rats with blood glucose concentrations greater than or equal to 18 mmol/l 
were considered diabetic. 
 
3.6.1.3. STZ-treated rats 
 
The rats were randomly divided into eight groups of 6 each, one group of 
normoglycaemic rats untreated, one group of rats treated with STZ without the plant 
extract, four test groups of STZ-diabetic rats treated with intraperitoneal injections of 
leaf methanol extract of the plant species; one dose per group (50,100, 200, 400 
mg/kg), one reference group of STZ-diabetic rats treated with 250 mg/kg of 
chlorpropamide administered orally and the last group of STZ-diabetic rats treated 
with 0.25 ml of DMSO administered intraperitoneally. The collection of blood 
samples was done from the tail vein of animals and measured by means of a 
glucometer. The blood glucose concentrations of normoglycaemic rats before 
 
 
 
 
46 
 
induction of diabetes were measured and considered as zero time (0 h) which was the 
time before treatment. After treatment, the blood glucose concentrations in each 
group were measured and recorded every 30 min for over 4 hours. The ability of the 
leaf methanol extract of Cnicus benedictus to significantly lower the blood glucose 
concentrations below 18 mmol/l was taken as an antidiabetic activity in this study 
(Williamson et al., 1996; Joy and kuttan, 1999). 
 
3.6.1.4. Oral glucose tolerance tests (OGTT) 
 
Modified method of Williamson et al. (1996)was used. Rats were randomly divided 
into seven groups of 6 each. All animals were fasted for 16 hours prior to the 
commencement of the experiments. One dose of glucose load (1.4 g/kg) was 
administered orally to fasted rats by means of a bulbed steel tube. The control group 
of fasted rats was treated with oral administration of glucose load followed by 
administration of 0.3 ml (i.p.) of physiological saline. Four test groups of fasted rats 
were treated with oral administration of glucose load followed by administration of 
leaf methanol plant extract, one dose per group (50,100, 200, 400 mg/kg, i.p.). The 
reference group of fasted rats was treated with oral glucose load followed by 
administration of 250 mg/kg (i.p.) of chlorpropamide. The last group of fasted rats 
was treated with oral glucose load followed by administration of 0.25 ml (i.p.) of 
DMSO. The collection of blood samples was done from the tail vein of animals and 
measured by means of a glucometer. The blood glucose concentrations of 
normoglycaemic rats at the end of the 16 h fasting period were measured and 
considered as zero time (0 h) which was the time before treatment. After treatment, 
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the blood glucose concentrations in each group were measured and recorded every 30 
min for over 4 hours.   
 
3.6.2. Assessment of the antinociceptive activity 
 
3.6.2.1. Acetic acid writhing test 
 
Acetic acid writhing test was used to assess the antinociceptive activity of C. 
benedictus. Mice were used in groups of eight per dose of plant extract, standard 
drugs, physiological saline or DMSO. The animals were kept individually in 
transparent perspex mouse cages before the commencement of the experiment. 
Control mice were pre-treated with physiological saline and for 15 min, after which 
each mouse was injected with 0.25 ml (i.p.) of 3 % acetic acid. The mice were left for 
5 min, and the writhes were counted for 30 min. The experiment was repeated using 
other groups of animals which were pre-treated for 15 min with graded doses of plant 
extract (i.p.), paracetamol (i.p.) or DMSO (i.p.) and for 30 min with indomethacin 
(i.p.) prior to injecting them with 0.25 ml (i.p.) of 3 % acetic acid. The experiment 
was also done using combined treatment of the lowest and sub-effective doses of the 
plant extract and indomethacin. The ability of the plant extract to significantly reduce 
the number of acetic acid-induced writhes was taken as antinociceptive activity 
(Garcia et al., 2004; Williamson et al., 1996; Koster et al., 1959). 
 
3.6.2.2. Hot-plate test 
 
Hot plate test was also used to assess the antinociceptive activity of C. benedictus. 
Mice were used in groups of eight per dose of plant extract, physiological saline, 
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morphine or DMSO. The animals were kept individually in transparent perspex 
mouse cages before the commencement of the experiment. Control mice were pre-
treated with physiological saline (i.p.) and after 15 min, each mouse was placed in an 
analgysiometer (TIIC, USA) maintained at 55°C. The pain threshold is considered to 
be reached when the animals lift and/or lick their hind paws or attempt to jump out of 
the animal enclosure. The time taken for animals to exhibit these characteristics, 
known as the reaction time, was noted by means of the ‘STOP’ button on the 
analgysiometer. The animals were tested before and then 15 min, 30 min, 45 min and 
60 min after administration of physiological saline (i.p.). The experiment was 
repeated using other groups of animals which were tested before and then 15 min, 30 
min, 45 min and 60 min after the intraperitoneal administration of graded doses of 
plant extract, morphine or DMSO.  The ability of the plant extract to delay the 
reaction time was taken as antinociceptive activity (Williamson et al., 1996; Eddy et 
al., 1953). 
 
3.7. Statistical analysis 
 
The data obtained from the antinociceptive activity and antidiabetic activity as well as 
oral glucose tolerance tests were analyzed using one way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparison test (GraphPad Prism, version 
5.0, GraphPad software, Inc., San Diego CA p2130, USA) and presented as mean ± 
Standard Error Mean (SEM). To determine the effects of leaf methanol extract of 
Cnicus benedictus, data were presented separately for the non-diabetic and STZ-
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diabetic rats. Data for control non-diabetic and STZ-diabetic were used as baseline. P 
value less than 5% (P<0.05) was considered to be statistically significant. 
 
3.8. Ethical considerations 
 
The ethics committee of the University of the Western Cape, South Africa approved 
the experimental protocol (15/6/96) used in the present study and this conforms to the 
“Guide to the care and use of animals in research and teaching” of the University. 
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CHAPTER 4 
RESULTS 
 
4.1 Acute toxicity 
 
Oral administration of leaf methanol extract of Cnicus benedictus given to mice at 
graded doses (200, 400, 800, 1600, 2000, 2400, 2800 and 3200 mg/kg) did not cause 
any death or acute toxicity symptoms in the animals. However, relatively high doses 
of methanol plant extract of C.benedictus (3600 and 4000 mg/kg, p.o.) tested caused 
1 and 2 deaths respectively. The no-adverse-effect-level (NOAEL) was obtained at 
3200 mg/kg (p.o.). The LD50 value for the plant species was found to be 4000 mg/kg 
(p.o.) 
 
4.2HPLC analysis 
 
The HPLC fingerprint of the leaf methanol extract of Cnicus benedictus showed 
distinct peaks at the following retention times, 6.387, 14.628, 18.431, 23.228 and 
29.829 minutes (Figure 3). 
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Figure 3 : HPLC fingerprint of methanol extract of Cnicus benedictus.  
 
4.3Effect of leaf methanol extract of Cnicus benedictus on blood glucose 
concentrations (mmol/l) of normoglycaemic rats (Table 3). 
 
Tablet3 shows effect of the plant extract on blood glucose levels of non-diabetic rats. 
All experiments were done on fasted normal rats. 
The blood glucose concentration before the administration of physiological saline 
was 6.44± 0.26 mmol/L. Administration of 0.3 ml (i.p.) of physiological saline did 
not significantly affect the blood glucose concentrations which ranging from 6.25± 
0.27 mmol/L to 6.52± 0.18 mmol/L over the 4 hr period of observation.  
C.benedictus (50 mg/kg, i.p.) did not significantly affect the blood glucose 
concentrations over the 4 hr of observation compared to the blood glucose 
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concentration before the administration of the plant extract. The percentage maximum 
reduction in blood glucose concentration after 4 hr following the administration of 50 
mg/kg of plant extract was 11%.  
Leaf methanol extract of C.benedictus (100 mg/kg i.p.) significantly reduced the 
blood glucose concentration after 2 ½ hr to 4 hr following the plant extract 
administration. The blood glucose concentration decreased from 6.08± 0.36 mmol/L 
before treatment to 3.30 ± 0.42 mmol/L, 4 hr after treatment with C.benedictus (100 
mg/kg, i.p.). The percentage maximum reduction in blood glucose concentrations 
after 4 hr of plant extract administration was 46%. 
 Leaf methanol extract of C,benedictus (200 mg/kg, i.p.) significantly reduced the 
blood glucose concentration after 1 ½hr to 4 hr following the plant extract 
administration. The blood glucose concentration decreased from 6.00± 0.16 mmol/L 
before treatment to 1.81± 0.11 mmol/L, 4 hr after treatment with the plant extract. 
The percentage maximum reduction in blood glucose concentrations after 4 hr of the 
plant extract administration was 70%.  
400 mg/kg (i.p.) of leaf methanol extract of C.benedictus reduced the blood glucose 
concentration to 1.30± 0.22 mmol/L after 4 hr of administration compared to the 
blood glucose concentration of 6.10± 0.26 mmol/L before treatment with the plant 
extract. The percentage maximum reduction in blood glucose concentrations after 4 
hr of the plant extract administration was 79%.  
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Administration of 250 mg/kg (i.p.) of chlorpropamide (standard drug) (Ojewole, 
2006) significantly reduced the blood glucose concentration after 30 min to 4 h of 
administration. The bloog glucose concentration decreased from 6.30 ± 0.30 mmol/L 
before treatment to 1.00± 0.77 mmol/L, 4 h after chlorpropramide (250 mg/kg, i.p.) 
administration. The percentage maximum reduction after 4 h of chlorpropramide 
administration was 84%.  
Administration of 0.25 ml (i.p.) of DMSO did not significantly alter the blood 
glucose concentrations of the normoglycaemic rats during the 4 h period of 
observation (Table 3).  
 
4.4 Effect of leaf methanol extract of Cnicus benedictus on blood glucose 
concentrations (mmol/l) of streptozotocin-treated (diabetic) rats (Table 4). 
 
Table 4 shows effect of the plant extract on blood glucose levels of diabetic rats. All 
experiments were done on fasted diabetic rats except the first row where the blood 
glucose levels were taken from untreated fasted normoglycaemic rats.  
The blood glucose concentrations (mmol/L) of untreated rats were not significantly 
altered during the 4 h period of observation. The blood glucose concentrations of 
untreated rats ranging from 4.78± 0.19 mmol/L to 4.75± 0.22 mmol/L over the 4 h 
period of administration. 
Streptozotocin (80 mg/kg, i.p.) significantly increased the blood glucose 
concentrations from pre-treatment value of 4.94 ± 0.29 mmol/L to 25.47± 1.68 
mmol/L after 30 min and 24.47± 1.17 mmol/L after 4 h of drug administration. 
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C.benedictus (50 mg/kg, i.p.) did not significantly alter the blood glucose 
concentrations over the 4 hr of observation compared to the blood glucose 
concentration before the administration of the plant extract. The percentage maximum 
reduction in blood glucose concentration after 4 hr following the administration of 50 
mg/kg of plant extract was 10.51%.  
Leaf methanol extract of Cnicus benedictus (100 mg/kg, i.p.) significantly reduced 
the blood glucose concentrations after 2h30 (17.47± 1.63 mmol/L) up to 4 h (13.80± 
1.42 mmol/L) following its administration. The percentage maximum reduction in 
blood glucose concentration after 4 h of the plant extract administration was 44.82%. 
Administration of 200 mg/kg (i.p.) of leaf methanol extract of the plant species 
significantly reduced the blood glucose concentration after 2 h (16.53± 1.42 mmol/L) 
up to 4 h (10.43± 1.08 mmol/L) following its administration. The percentage 
maximum reduction in blood glucose concentration after 4 h of plant administration 
was 60.04%. 
Leaf methanol extract of C.benedictus (400 mg/kg, i.p.) significantly reduced the 
blood glucose concentration after 1 h (16.30± 1.34 mmol/L) up to 4 h (9.10± 1.52 
mmol/L) following its administration. The percentage maximum reduction in blood 
glucose concentrations after 4 h of plant administration was 66.04%. 
Chlorphenamine (250 mg/kg,i.p.) (Ojewole, 2006) significantly reduced the blood 
glucose concentration after 1 h (15.17± 1.64 mmol/L) up to 4 h (7.57± 0.23 mmol/L) 
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following its administration. The percentage maximum reduction in blood glucose 
concentration after 4 h of plant administration was 71.71%. 
Administration of 0.25 ml (i.p.) of DMSO did not significantly alter the blood 
glucose concentrations of the streptozotocin-treated rats during the 4 h period of 
observation (Table 4).  
 
4.5 Effect of leaf methanol extract of Cnicus benedictus on oral glucose tolerance 
test in normoglycaemic rats (Table 5). 
 
Table 5 shows the effect of the plant extract on blood glucose levels of non-diabetic 
rats after oral glucose load of 1.4 g/kg. All experiments were done on fasted normal 
rats. An increase in blood glucose concentration was observed in all animals at 30min 
after oral administration of glucose load. 
0.3 ml of physiological saline did not significantly reduce the rise in blood glucose 
levels during the 4 h period of observation. The same observation was made with 50 
mg/kg (i.p.) of the plant extract. 50 mg/kg (i.p.) of methanol plant extract given 
following the oral glucose load did not significantly reduced the rise in blood glucose 
levels over the 4 h of observation.  
However, 100 and 200 mg/kg (i.p.) of methanol plant extract given following the oral 
glucose load significantly reduced the increased blood glucose levels. 100 mg/kg 
(i.p.) of methanol plant extract reduced the increased blood glucose concentrations 
from the second to the fourth hour of observation with a percentage maximum 
reduction of 42.45%.  200 mg/kg (i.p.) of methanol plant extract reduced the blood 
 
 
 
 
56 
 
glucose concentration from 1h 30 min to the fourth hour of observation period with a 
percentage maximum reduction of 66.20%. 
Administration of 400 mg/kg (i.p.) of methanol plant extract following oral glucose 
load significantly reduced the rise in blood glucose levels from 7.83±0.36 to 
3.17±0.33 after 1h30 with a percentage maximum reduction of 70.75%. 
Administration of chlorpropamide 250 mg/kg (i.p.) (Ojewole, 2006) following oral 
glucose load significantly reduced the increased blood glucose concentration from the 
1 h through to the fourth hour of observation with a percentage maximal reduction of 
79.04%.  
Administration of DMSO 0.25 ml (i.p.) did not significantly alter the rise in blood 
glucose concentration over the 4 h of observation period.  
 
4.6 Effect of leaf methanol extract of C. benedictus on acetic acid-induced 
writhing 
Substantial number of writhes was produced by 0.25 ml (i.p.) of 3% acetic acid in 
mice. Leaf methanol extract of C. benedictus (25-400 mg/kg, i.p.) significantly 
reduced the number of 3% acetic acid-induced writhes in mice. The percentage 
inhibition of the writhes ranged from 67.95% by 25 mg/kg (i.p.) of the plant extract to 
73.71% by C. benedictus (400 mg/kg, i.p.). The dose of 12.5 mg/kg (i.p.) of the leaf 
methanol extract of C. benedictus did not affect the number of 3% acetic acid-
induced writhes in any significant manner.   
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Indomethacin (20 mg/kg, i.p.) or paracetamol (500 mg/kg, i.p.) significantly reduced 
the number of writhes produced by 0.25 ml (i.p.) of 3% acetic acid and the percentage 
inhibition of the writhes was 75.44 and 6.18% respectively. Indomethacin (10 mg/kg, 
i.p.) or DMSO (0.25ml, i.p.) did not significantly affect the number of 3% acetic acid-
induced writhes.  
However, the combined treatment of the lowest and sub-effective doses of leaf 
methanol extract of C. benedictus (12.5 mg/kg, i.p.) and indomethacin (10 mg/kg, 
i.p.) significantly reduced the number of writhes produced by 3% acetic acid and the 
percentage inhibition of the writhes was 58.32% (Table6) 
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Table 3: Effect of leaf methanol extract of Cnicus benedictus.on blood glucose concentration (mmol/L) of normoglycaemic (normal) 
rats 
 
   
Treatment Before  After treatment             
    
Maximal  %  
groups treatment 
        
  
reduction  Maximal 
 
0 h 30min 1h 1h30 2h 2h30 3h 3h30 4h  reduction 
 
Ps                         
0.3 ml 6.44 ±0.26 6.52 ±0.18 6.37 ±0.37  6.30 ±0.29  6.43 ±0.61  6.35 ±0.22  6.29 ±0.17  6.25 ±0.27  6.27 ±0.18 0.19 2.95 
Cnicus Benedictus  
          50 mg/kg 6.78 ±0.16 7.01 ±025 6.88 ±0.41  6.78 ±0.42  6.76 ±0.42  6.75 ±0.33  6.50 ±0.36  6.43 ±0.35  6.01 ±0.30 0.77 11.36 
100 mg/kg 6.08 ±0.36 6.62 ±0.27  6.30 ±0.27  5.93 ±0.28  5.38 ±0.48  4.70 ±0.42*  4.55 ±0.42*  4.43 ±0.40*  3.30 ±0.42* 2.78 45.72 
200 mg/kg 6.00 ±0.16 6.83 ±0.33  5.75 ±0.47  4.03 ±0.44*  2.68 ±0.29*  2.18 ±0.23*  1.97 ±0.18*  1.86 ±0.13*  1.81 ±0.11* 4.19 69.83 
400 mg/kg 6.10 ±0.26 6.01 ±0.43 5.34 ±0.18  3.12 ±0.25*  2.24 ±0.11*  2.06 ±0.20*  1.82 ±0.35*  1.55 ±0.16*  1.30 ±0.22* 4.8 78.69 
Chlorpropamide 
          250 mg/kg 6.30 ±0.30 4.43 ±0.40* 3.72 ±0.17*  3.33 ±0.17*  3.03 ±0.21*  3.48 ±0.49*  2.7 ±0.12*  2.3 ±0.10*  1.00 ±0.77* 5.3 84.13 
DMSO 
           0.25 ml 6.21 ±0.24 6.38 ±0.37 5.98 ±0.50 5.92 ±0.47 6.08 ±0.44 5.95 ±0.47 6.02 ±0.52 6.15 ±0.47 6.12 ±0.45 0.29 4.67 
 
                      
*p<0.05     
           Values are expressed as mean± SEM.  ANOVA (n=6). 
        PS: Physiological saline 
DMSO: Dimethylsulfoxide 
          
 
 
 
 
59 
 
 
 
Table 4: Effect of leaf methanol extract of Cnicus benedictus on blood glucose concentrations (mmol/L) of streptozotocin-treated diabetic rats 
          
   
Treatment Before  After treatment                Maximal          %  
groups treatment 
 
                 reduction   Maximal 
 
 
0 h STZ 30min 1h 1h30 2h 2h30 3h 3h30 4h     reduction 
 
Untreated 4.78 ±0.19 
 
4.9 ±0.25 4.1 ±0.42  4.9 ±0.33  4.5 ±0.36  4.88 ±0.24  4.93 ±0.37  4.75 ±0.30  4.75 ±0.22 - - 
Streptozotocin (STZ) 
           80 mg/kg 4.94 ±0.29  25.77 ±1.42 25.47 ±1.68 25.37 ±1.01  25.03 ±1.55  24.38 ±1.28  24.60 ±1.17  24.15 ±1.44  24.55 ±1.76  24.47 ±1.17 1.62 6.29 
Cnicus benedictus 
           50 mg/kg 4.87 ±0.31 25.78 ±1.39 28.83 ±1.47 28.07 ±1.29  27.95 ±1.10  25.93 ±1.09  26.60 ±1.31  25.70 ±1.17  23.90 ±1.30  23.07 ±1.48 2.71 10.51 
100 mg/kg 4.68 ±0.23 25.01 ±1.54 23.48 ±1.31 22.57 ±1.54  20.67 ±1.61  21.22 ±1.28  17.47 ±1.63*  15.62 ±1.55*  14.23 ±1.06*  13.80 ±1.42* 11.21 44.82 
200 mg/kg 4.68 ±0.34 26.10 ±1.27 30.30 ±1.88 27.13 ±1.61  24.47 ±1.67  16.53 ±1.42*  14.65 ±1.01*  13.01 ±1.06*  11.90 ±1.45*  10.43 ±1.08* 15.67 60.04 
400 mg/kg 4.82 ±0.17 26.80 ±1.32 25.90 ±1.22 16.30 ±1.34*  15.89 ±1.19*  14.78 ±1.22*  13.85 ±1.36*  12.68 ±1.43*  11.11 ±1.21*  09.10 ±1.52* 17.7 66.04 
Chlorpropamide 
           250 mg/kg 4.97 ±0.26 26.76 ±1.52 28.46 ±1.52 15.17 ±1.64*  13.95 ±1.37*  11.53 ±1.70*  11.85 ±1.77*  10.23 ±1.48*  09.45 ±1.45*  07.57 ±0.23* 19.19 71.71 
DMSO 
            0.25 ml 5.13 ±0.18 24.32 ±1.25 24.32 ±1.25 24.75 ±1.02  24.78 ±1.04  24.65 ±1.20  24.50 ±1.10  24.43 ±1.20  24.10 ±1.14  24.18 ±1.04 0.22 0.90 
 
                        
*p<0.05     
            Values are expressed as mean± SEM.  ANOVA (n=6). 
        PS: Physiological saline 
DMSO: Dimethylsulfoxide 
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Table 5: Effect of leaf methanol extract of Cnicus benedictus on oral glucose tolerance test in normoglycaemic (normal) rats. 
            
    
Treatment Before  After treatment              Maximal          %  
groups treatment 
        
 reduction   Maximal 
 
0 h 30min 1h 1h30 2h 2h30 3h 3h30 4h 
 
Reduction 
 
Ps                       
0.3 ml 4.70 ±0.10 6.73 ±0.37 6.08 ±0.22  6.63 ±0.20  6.48 ±0.11  6.38 ±0.22  5.57 ±0.20  5.43 ±0.14  5.55 ±0.23 - - 
Cnicus Benedictus  
          50 mg/kg 4.92 ±0.17 9.03 ±0.55 7.32 ±0.67  6.95 ±0.77  6.42 ±0.74  6.28 ±0.68  6.12 ±0.55  5.90 ±0.67  5.40 ±0.59 - - 
100 mg/kg 4.90 ±0.24 7.87 ± 0.76 6.73 ±0.52  6.58 ±0.68  4.08 ±0.52*  3.46 ±0.50*  3.63 ±0.45*  3.12 ±0.58*  2.82 ±0.54* 2.08 42.45 
200 mg/kg 5.00 ±0.18 7.58 ±0.61  5.22 ±0.53  3.33 ±0.45*  2.30 ±0.23*  2.05 ±0.25*  1.83 ±0.19*  1.76 ±0.11*  1.69 ±0.09* 3.31 66.2 
400 mg/kg 4.65 ±0.11 7.83 ±0.36 6.25 ±0.19  3.17 ±0.33*  3.06 ±0.12*  2.07 ±0.20*  1.63±0.24*  1.58 ±0.31*  1.36 ±0.17* 3.29 70.75 
Chlorpropamide 
          250 mg/kg 5.01 ±0.08 8.25 ±0.58 3.25 ±0.50*  3.23 ±0.29*  2.55 ±0.18*  1.60 ±0.12*  1.48 ±0.10*  1.23 ±0.17*  1.05 ±0.20* 3.96 79.04 
DMSO 
           0.25 ml 4.90 ±0.06 8.62 ±0.29 7.73 ±0.37 7.97 ±0.43 7.83 ±0.25 7.85 ±0.30 7.30 ±0.39 6.97 ±0.14 6.75 ±0.10 - - 
 
                      
*p<0.05     
           Values are expressed as mean± SEM.  ANOVA (n=6). 
        PS: Physiological saline 
DMSO: Dimethylsulfoxide 
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4.7 Effect of leaf methanol extract of C. benedictus on hot-plate induced nociception 
Mice pre-treated with physiological saline reacted to hot-plate thermal stimulation at 50◦C–55◦C 
either by lifting and licking their paws or attempting to jump out of the beaker. This 
manifestation occurred within 5.22± 0.10 sec in the first 15 min and 5.36± 0.77 sec, 60 min later 
after the intraperitoneal injection of 0.25ml of physiological saline.  
Leaf methanol extract of C. Benedictus (25–400 mg/kg, i.p.) significantly delayed the reaction 
times of the animals to hot-plate thermal stimulation 15 min after treatment and over the 1 h 
period of measurement. Similarly, morphine (10 mg/kg, i.p.) significantly delayed the reaction 
time of the mice to the hot-plate-induced thermal stimulation over the 1 h period of 
measurement. Leaf methanol extract of C. Benedictus (12.5 mg/kg, i.p.) and DMSO (0.25ml, 
i.p.) did not significantly alter the reaction time of the mice to the hot-plate-induced thermal 
stimulation over the 1h period of measurement.  
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Table 6: Effect of leaf methanol extract of C. benedictus on acetic acid-induced 
writhing in mice. 
       
 
      Treatment Dose Number of writhes Percentage 
  
Groups (mg /kg)       Mean  ±   SEM inhibition ( % ) 
  
PS 
 
53.67 8.12     -  
   
C.benedictus 
      
 
12.5 46.17 7.34 13.97 
  
 
25 17.20* 4.03 67.95 
  
 
50 16.31* 3.55 69.61 
  
 
100 15.28* 4.46 71.53 
  
 
200 15.62* 2.28 70.9 
  
 
400 14.11* 1.84 73.71 
  Indomethacin 
     
 
10 40.39 4.63 24.74 
  20 13.18* 1.91 75.44 
   
C.benedictus 12.5 
      +indomethacin    10                   22.37* 3.6 58.32 
   
Paracetamol 500 16.54* 1.18 69.18 
   
DMSO 
 
0.25 ml 
 
48.87 
 
9.52 
 
8.94 
   
 *p<0.05     
      Values are expressed as mean± SEM.  ANOVA (n=6). 
 PS: Physiological saline 
             DMSO: Dimethylsulfoxide 
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Table 7: Effects of leaf methanol extract of Cnicus benedictus on hot plate-induced 
nociception in mice. 
       
 
Treatment Dose 
Reaction 
time  (s)       
groups (mg/kg) 0 min 15 min 30 min 45 min 60 min 
 
PS 0.25 ml 5.40 ±0.10 5.22 ±0.64 5.41 ±0.72  6.23 ±0.90  5.36 ±0.77 
Cnicus benedictus 
     
 
12.5 5.73 ±0.73 5.92 ±0.25 5.69 ±0.61 5.56 ±0.92 5.88 ±0.34 
 
25 5.76 ±0.28 12.06 ±0.52* 13.24 ±0.18* 13.04 ±0.25* 12.11 ±0.52* 
 
50 5.17 ±0.11 12.02 ±0.37* 13.13 ±0.20* 13.36 ±0.10* 12.64 ±0.12* 
 
100 5.81 ±0.72 13.43 ±0.21* 13.37 ±0.80* 12.54 ±0.18* 11.36 ±0.34* 
 
200 5.54 ±0.08 13.55 ±0.25* 12.31 ±0.42* 13.66 ±0.28* 12.70 ±0.25* 
 
400 5.81 ±0.19 13.85 ±0.52* 13.19 ±0.60* 14.22 ±0.87* 12.44 ±0.35* 
Morphine 10 5.52 ±0.16 14.11 ±0.44* 14.48 ±0.27* 14.09 ±0.09* 12.85 ±0.30* 
DMSO 0.25 ml 5.66 ±0.77 5.72 ±0.29 5.90 ±0.91 5.48 ±0.62 5.39 ±0.37 
              
*p<0.05 compared to physiological saline (0.25 ml, i.p.) control, ANOVA (n = 8).  
 The reaction time in seconds was expressed as Mean±SEM. 
  PS: Physiological saline  
    DMSO: Dimethylsulfoxide 
     
 
 
 
 
 
 
 
 
 
 
64 
 
CHAPTER 5 
DISCUSSION 
 
Diabetes is a chronic metabolic condition recognized worldwide as an important 
cause of premature death and disability, especially in the developing world. 
According to the WHO, the number of adult people suffering from diabetes has 
almost quadrupled since 1980 mainly due to the increase number of people living 
with diabetes mellitus type 2 and related factors driving it including obesity and 
overweight. Additional 2.2 million of deaths are associated with the increase risk of 
cardiovascular diseases due to the high blood glucose concentrations. The cost of 
managing diabetes can be catastrophic in poor population. There is an urge to seek 
other possibilities of managing diabetes in order to reduce the high rate of mortality. 
In fact, about 80% of the population relies on herbal medicines especially in 
developing countries due to the low cost and availability of these medicines.  The 
WHO has requested several governments to include herbal medicines with proven 
efficacy and safety in their healthcare programs (Marini-Bettelo, 1980; Van Wyk et 
al., 1997; World Health Organization, 2010; International Diabetes Federation, 2013)  
One of such herbal medicines which could be included in the South African 
healthcare program is Cnicus benedictus L, commonly called Karmedick in 
Afrikaans. The plant species is widely used by traditional healer in rural area of South 
Africa to treat various ailment including diabetes and pain (Van Wyk et al., 1997). In 
order to scientifically corroborate the claim made by traditional healers of the 
therapeutic success of this plant species, this present study was undertaken to 
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investigate the antidiabetic activity of C.benedictus in streptozotocin-induced diabetic 
rats and to verify the antinociceptive activity of the plant extract.  
 
In the present study, no signs of acute toxicity symptoms or death in mice were 
observed with dose of leaf methanol extract of C.benedictus from 50 mg/kg (p.o.) to 
3200 mg/kg (p.o.). However, death was observed at the doses of 3600-4000 mg/kg 
(p.o.). The LD50 value of the plant extract when given orally was found to be 4000 
mg/kg suggesting that it may be safe in mice at relatively high doses. It is pertinent to 
mention that traditional medicine practitioners administer the plant species orally in 
form of infusion in the treatment of diabetes and other ailments (Van Wyk et al., 
1997).  
HPLC study was carried out to characterize C.benedictus and the HPLC fingerprint 
obtained in this study revealed characteristic distinct peaks of the plant species at the 
following retention times (minutes), 6.387, 14.628, 18.431, 23.228 and 29.829. 
Hypoglycaemic effect 
In this study, physiological saline (0.3 ml, i.p.) did not significantly alter the blood 
glucose concentrations of fasted normoglycaemic (non-diabetic) rats. Similarly, 
DMSO (0.25 ml, i.p.) did not significantly produce changes in the blood glucose 
concentrations of non- diabetic rats. However, leaf methanol extract of C.benedictus 
(100 and 200 mg/kg, i.p.) significantly reduced the blood glucose concentrations of 
non-diabetic rats. Further significant reduction in blood glucose concentrations was 
observed with 400 mg/kg (i.p.) of leaf methanol extract. Chlorpropramide (250 
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mg/kg, i.p.), a standard oral antidiabetic drug, significantly reduced the blood glucose 
concentrations of fasted normoglycaemic rats. Chlorpropramide, a first generation 
sulphonylurea oral antidiabetic or hypoglycaemic drug, is thought to exert its 
hypoglycaemic effect by stimulating and increasing the release of endogenous insulin 
from pancreatic beta cells, and also promoting peripheral tissue glucose update and 
distribution (Schneider et al., 1987). Like chlorpropramide, the leaf methanol extract 
(100 – 400 mg/kg, i.p.) was shown in this study to exhibit hypoglycaemic effect. 
Streptozocin (STZ, 80 mg/kg, i.p.) was used to induce diabetes in rats in this study. 
According to Ojewole (2006), STZ-induced diabetic rat model is a good experimental 
protocol for antidiabetic studies especially Type 2 diabetes. STZ is thought to cause 
diabetes by destroying the pancreatic beta cells thereby reducing the release of insulin 
which may lead to hyperglycaemia (Schneider et al., 1987).  In the present study, leaf 
methanol extract of C.benedictus (100 – 400 mg/kg ,i.p.) and chlorpropramide (250 
mg/kg, i.p.) separately and significantly reduced the blood glucose concentrations of 
STZ-induced diabetic rats. This supports the assertion that the leaf methanol extract 
of the plant species has hypoglycaemic effect. Even though the mechanism of the 
hypoglycaemic effect of C. benedictus is not known but since both the leaf methanol 
extract and chlorpropramide similarly reduced the blood glucose concentrations of 
STZ-induced diabetic rats, it is possible to suggest that C. benedictus maybe 
producing its hypoglycaemic effect either by promoting peripheral tissue glucose 
uptake and utilization or either mechanisms that do not involve insulin considering 
that STZ is known to selectively destroy pancreatic beta cells thus blocking insulin 
production.  
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The phytochemical analysis carried out by previous studies revealed that 
C.benedictusis mainly composed of sesquiterpene lactone glycosides from which the 
principal component is cnicin. Additionally triterpenoids, ligans, tannins and essential 
oil such as cinnamaldehyde are present amongst other chemical metabolites. The 
plant species also contained alkaloids, phenolic compounds, saponins, starch and 
flavonoids such as apigenin-7-0-glucoside (Hule et al., 2011). Several authors in their 
studies have reported flavonoids, alkaloids and phenolic compounds to be bioactive 
antidiabetic chemicals (Oliver-Bever, 1986).  
An extensive study on flavonoids has demonstrated that flavonoid compounds have 
antidiabetic activity (Fawzy et al., 2008). Li et al in their study of Malus toringoides 
showed that flavonoids have hypoglycemic activity in experimental diabetic animals 
(Li et al., 2014). The study done by Rauter et al showed that after 7 days of treatment, 
apigenin (a flavoinoid) significantly lowered the blood glucose levels of diabetic 
animals (Rauter et al., 2010). However, flavonoids are not the only phytochemicals 
with antidiabetic activity. In fact, Junk et al in their study on antidiabetic agents from 
medicinal plants showed that flavonoids as well as alkaloids exhibit antidiabetic 
activity (Junk et al., 2006). A study by babu et al., (2007) showed that 
cinnamaldehyde, a potential antidiabetic agent, given for one month to 
streptozotocin-induced diabetic rats significantly reduced the plasma glucose 
concentrations of the animals. Therefore it is possible to speculate that the presence 
of flavonoids, alkaloids and cinnalaldehyde may be contributing at least in part, to the 
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antidiabetic activity of Cnicus benedictus observed in normoglycaemic rats and 
streptozotocin-induced diabetic rats in our study.  
In the oral glucose tolerance test done in this project, administration of leaf methanol 
extract of C. benedictus following oral glucose load on fasted normoglycaemic rats 
significantly reduced the increased blood glucose concentrations. Further supports the 
claim that the plant species has hypoglycaemic effect on normal fasted animals when 
compared to the results obtained from chlorpropramide the hypoglycaemic reference 
drug, used.  
Analgesic effect 
In this study, the leaf methanol extract of C. benedictus significantly antagonized the 
acetic acid induced writhes in mice. Indomethacin or paracetamol also significantly 
antagonized the writhes produced by acetic acid in mice. Combined sub effective 
doses of leaf methanol extract of C.benedictus and indomethacin significantly 
antagonized acetic acid induced writhes in mice. According to Satyanarayana et al. 
(2004), acetic acid may be inducing writhes by stimulating the production of 
prostaglandins. Indomethacin and paracetamol, the standard analgesic drugs, have 
been shown to inhibit prostaglandin synthesis peripherally and in the brain 
respectively (Rang et al., 2012, Flower and Vane, 1972). Therefore, it is not 
surprising that both indomethacin and paracetamol significantly antagonized writhes 
produced by acetic acid. Since C.benedictus and also the combined treatment of sub-
effective doses of C.benedictus and indomethacin antagonized writhes produced by 
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acetic acid, it is possible to suggest that the antinociceptive activity of the plant 
extract may be underpinned by prostaglandin mechanism(s).  
It is also observed in the study that the leaf methanol extract of C.benedictus 
significantly delayed the reaction time of mice to thermal stimulation produced by the 
hot plate. Morphine, a known standard centrally acting analgesic drug, was shown in 
this study to significantly delay the reaction time of mice to thermal stimulation 
produced by the hot-plate. According to Koster et al. (1959), Eddy and Leimback 
(1953), acetic acid writhing and hot-plate tests are used to assess analgesic drugs with 
peripheral and central effects respectively. Since C.benedictus significantly 
antagonized writhes produced by acetic acid and thermal stimulation produced by 
hot-plate, it is possible to suggest that the plant species has both peripheral and 
central antinociceptive activities. 
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CHAPTER 6 
 
CONCLUSION 
 
The data obtained from this present investigation provide evidence that Cnicus 
benedictus has hypoglycaemic effects on blood glucose concentrations of diabetic 
rats and may be effective in cases of glucose tolerance impairment. However, it can 
be speculated that the antidiabetic activity of C.benedictus may be due to non-specific 
mechanism and not due to the stimulation of insulin release from pancreatic beta cells 
since streptozotocin used in this study is well known to work by depleting the 
pancreatic beta cells thus reducing the release of insulin from these cells. Also, the 
synergistic effect of different bioactive chemicals may have a crucial contribution to 
the potential hypoglycaemic action of the plant species.  
Furthermore, the results obtained from this study confirm that C.benedictus has 
antinocieptive activity which may involve prostaglandins mechanism and certain 
central pain receptors.  
The LD50 of the plant revealed that the plant is safe and/ or non-toxic in mice when 
doses less than 3200 mg/kg of body weight of animals.  
All the above data obtained from C.benedictus studies indicate that the plant species 
has both antidiabetic and antinociceptive activities which support or justify the 
reported folkloric and anecdotal use of Cnicus benedictus in the treatment and/ or 
management of diabetes and pain in some southern Africa regions.  
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However, we recommend more studies to be done on toxicity of the plant species to 
further enhance the safety profile of Cnicus benedictus. Pharmacological and 
biochemical studies could be undertaken to elucidate the mechanism of action of the 
antidiabetic and antinociceptive activities of the plant species. 
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